



The compensatory effect of education as revealed by resting-state electroencephalographic alpha rhythms in patients with dementia due to Parkinson's disease: findings from an exploratory study

Susanna Lopez · Claudio Del Percio · Roberta Lizio · Giuseppe Noce · Dharmendra Jakhar · Andrea Soricelli · Marco Salvatore · Bahar Güntekin · Görsev Yener · Federico Massa · Dario Arnaldi · Francesco Famà · Matteo Pardini · Raffaele Ferri · Filippo Carducci · Bartolo Lanuzza · Fabrizio Stocchi · Laura Vacca · Chiara Coletti · Moira Marizzoni · John-Paul Taylor · Lutfu Hanoğlu · Nesrin Helvacı Yılmaz · İlayda Kıyı · Yağmur Özbek-İşbitiren · Anita D'Anselmo · Laura Bonanni · Roberta Biundo · Fabrizia D'Antonio · Giuseppe Bruno · Angelo Antonini · Franco Giubilei · Sofia Cuoco · Paolo Barone · Giovanni B. Frisoni · Rossella Rotondo · Francesca De Pandis · Claudio Babiloni

Received: 19 September 2024 / Accepted: 7 May 2025

© The Author(s) 2025

Abstract Here, we investigated whether educational attainment influences the neurophysiological mechanisms underlying vigilance regulation, as reflected in resting-state eyes-closed electroencephalographic (rsEEG) rhythms, in patients with dementia due to

Parkinson's (PDD) and Lewy body disease (DLB). Clinical, demographic, and rsEEG data were obtained from an international database, including PDD patients ($N=75$), DLB patients ($N=50$), and cognitively unimpaired older controls (Healthy; $N=54$). Each group was partitioned into low (Edu-) and high (Edu+) educational attainment subgroups, matched for age, sex, and cognitive-motor status. We analyzed rsEEG rhythms across the individual delta, theta, and

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1007/s11357-025-01703-9>.

S. Lopez · C. Del Percio · R. Lizio · D. Jakhar · F. Carducci · C. Babiloni (✉)
Department of Physiology and Pharmacology "Vittorio Ersamer", Sapienza University of Rome, P. Le A. Moro 5, 00185 Rome, Italy
e-mail: claudio.babiloni@uniroma1.it

G. Noce · A. Soricelli · M. Salvatore
IRCCS Synlab SDN, Naples, Italy

A. Soricelli
Department of Medical, Movement and Well-Being Sciences, University of Naples Parthenope, Naples, Italy

B. Güntekin
Department of Biophysics, School of Medicine, Istanbul Medipol University, Istanbul, Turkey

G. Yener
Faculty of Medicine, Izmir University of Economics, Izmir, Turkey

F. Massa · D. Arnaldi · F. Famà · M. Pardini
Dipartimento Di Neuroscienze, Oftalmologia, Genetica, Riabilitazione e Scienze Materno-Infantili (DiNOGMI), Università Di Genova, Genoa, Italy

F. Massa
Clinica Neurologica, IRCCS Ospedale Policlinico San Martino, Genoa, Italy

D. Arnaldi · F. Famà
Neurofisiopatologia, IRCCS Ospedale Policlinico San Martino, Genoa, Italy

R. Ferri · F. Carducci · B. Lanuzza
Oasi Research Institute – IRCCS, Troina, Italy

F. Stocchi · L. Vacca · C. Coletti
IRCCS San Raffaele, Rome, Italy

F. Stocchi · F. De Pandis
Telematic University San Raffaele Rome, Rome, Italy

alpha frequency bands. Cortical rsEEG source topography was estimated using eLORETA freeware. In the Healthy group, Edu+ participants exhibited significantly greater widespread rsEEG alpha source activities compared to Edu- participants, possibly reflecting neuroprotective neurophysiological mechanisms. Conversely, in the PDD group, Edu+ patients showed lower widespread rsEEG alpha source activities than Edu- patients, possibly indicating compensatory mechanisms. No significant differences in rsEEG source activities were observed between DLB-Edu+ and DLB-Edu- patients. Educational attainment may be associated with compensatory mechanisms that counteract the abnormal neurophysiological processes underlying rsEEG alpha rhythms and vigilance regulation in PDD patients, but not in DLB patients. Future studies combining rsEEG and neuroimaging techniques should investigate the metabolic and functional connectivity correlates of these putative compensatory mechanisms in the PDD brain. Early education may be a key investment for national governments, especially in low-income countries, to prevent the cognitive deficits of Parkinson's disease along aging, thereby reducing the unbearable social and economic burden.

M. Marizzoni

Biological Psychiatry Unit, IRCCS Istituto Centro San Giovanni Di Dio Fatebenefratelli, Brescia, Italy

J.-P. Taylor

Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK

L. Hanoğlu

Department of Neurology, School of Medicine, Istanbul Medipol University, Istanbul, Turkey

N. H. Yılmaz

Parkinson's Disease and Movement Disorders Center (PARMER), Istanbul Medipol University, Istanbul, Turkey

İ. Kızı · Y. Özbek-İşbitiren

Health Sciences Institute, Department of Neurosciences, Dokuz Eylül University, Izmir, Turkey

A. D'Anselmo · L. Bonanni

Department of Aging Medicine and Sciences, University "G. d'Annunzio" of Chieti-Pescara, Chieti, Italy

Keywords Parkinson's disease dementia (PDD) · Lewy body dementia (DLB), Alpha resting-state electroencephalographic (EEG) rhythms · Exact low-resolution brain electromagnetic source tomography (eLORETA) · Education · Cognitive reserve

Introduction

According to the World Health Organization facts (<https://www.who.int/>), five million people suffer from senile dementia, with about 60% of them due to Alzheimer's disease (AD), which is caused by brain amyloidosis and tauopathy. Approximately 20% of dementia cases are attributed to Parkinson's disease dementia (PDD) and dementia with Lewy bodies (DLB). These neurodegenerative diseases are characterized by intraneural inclusions of Lewy bodies (primarily composed of α -synuclein protein)

R. Biundo · A. Antonini

Parkinson and Movement Disorders Unit, Study Center for Neurodegeneration (CESNE), Center for Rare Neurological Diseases (ERN RND), Department of Neuroscience, University of Padua, Padua, Italy

R. Biundo

Department of General Psychology, University of Padova, Padua, Italy

F. D'Antonio · G. Bruno

Department of Human Neurosciences, Sapienza University of Rome, Rome, Italy

F. Giubilei

Department of Neuroscience, Mental Health, and Sensory Organs, Sapienza University of Rome, Rome, Italy

S. Cuoco · P. Barone

Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", Neuroscience Section, University of Salerno, Baronissi, Italy

G. B. Frisoni

Laboratory of Neuroimaging of Aging (LANVIE), University of Geneva, Geneva, Switzerland

G. B. Frisoni

Geneva Memory Center, Department of Rehabilitation and Geriatrics, Geneva University Hospitals, Geneva, Switzerland

R. Rotondo · F. De Pandis · C. Babiloni

Hospital San Raffaele Cassino, Cassino, FR, Italy

and neurites in the basal ganglia (especially in PDD) and cortical regions (especially in DLB) [1, 2], leading to axonal dysfunction, neuronal loss, and brain neurodegeneration. Both diseases are marked by dopamine depletion in basal ganglia circuits and cholinergic depletion from forebrain cholinergic neurons [3–5].

In Parkinson's disease (PD), motor symptoms such as resting tremor, rigidity, or bradykinesia are early core clinical manifestations, typically preceding the gradual onset of cognitive deficits, which may eventually lead to dementia [1]. In contrast, DLB patients often present cognitive deficits before or concurrently with motor symptoms [1]. Furthermore, DLB patients are more likely to experience visual hallucinations, marked diurnal cognitive fluctuations, and rapid-eye-movement sleep behavior disorder (RBD) [6]. In both PDD and DLB, cognitive deficits primarily affect executive, attentional, and verbal functions [1, 7–10].

The individual variability of neurodegenerative disease's course from the onset of clinical manifestations to dementia depends on various factors, including the neurobiological and neurophysiological features preventing or contrasting the disease, which form a sort of brain cognitive reserve (CR). Such a reserve may be developed over a person's lifetime in relation to high educational attainment and the related intellectual activities in work occupation, cultural interests, and creative/leisure experiences [11]. The physiological bases of CR remain unclear. CR may be associated with enhanced neurogenesis, synaptic plasticity, neuronal efficiency in neuromodulation systems, and the brain's ability to reorganize functional connectivity flexibly to compensate for neuropathological and neurodegenerative processes [11–16]. CR cannot be measured directly but can be estimated using proxy factors such as general intelligence, education level, and the intellectual demands of one's occupation over a lifetime, often combined through comprehensive tests and questionnaires [15, 16].

A full and longitudinal characterization of all these factors is essential to better interpret their synergic contributions to CR. Educational attainment is frequently used as a simple and effective CR proxy in scientific research due to its strong association with various factors that enhance brain resilience. Education has a clear and significant impact on brain health, making it an essential early-life strategy for

preventing neurodegenerative disorders [17]. Formal educational attainment is an important indicator of socioeconomic disparities [18–20] significantly influencing brain health [20–22], providing a robust reserve against cognitive decline, and reducing the risk of developing dementia [23]. Extensive evidence shows that enhanced educational attainment effectively counters the adverse effects of brain damage in conditions such as Alzheimer's disease (AD), frontotemporal dementia (FTD), dementia with Lewy bodies (DLB), and other neurological and psychiatric disorders [17].

CR was initially introduced to explain better-than-expected cognitive performance in Alzheimer's disease dementia (ADD) patients despite significant brain neuropathology observed through autaptic histological analyses [24] and in vivo biomarkers of AD neuropathology [11, 15, 25]. Specifically, CR's *neuroprotective mechanisms* have been hypothesized to explain why older adults with higher CR (Edu+) experience a delayed onset of cognitive deficits compared to those with lower CR (Edu-); at the same time, CR's *compensatory (resilient) mechanisms* have been hypothesized to explain why Edu+ patients maintain cognitive function despite greater brain atrophy and hypometabolism, as shown by MRI and PET biomarkers [11, 15, 26–37]. The compensatory mechanism due to education attainment could also explain the results on clinical-cognitive status and autaptic neuropathological burden (e.g., neocortical and hippocampal neuritic plaques, neocortical cerebral amyloid angiopathy, and Braak stage for tau and tangles) obtained in hundreds of older patients with dementia by the ECLIPSE Collaborative Members [38].

CR's effects are not limited to cognitive function and brain integrity, as revealed by neuroimaging techniques. They also influence the brain's neurophysiological oscillatory mechanisms that regulate cortical arousal and vigilance during wakefulness, which are reflected by changes in electroencephalographic (rsEEG) rhythms recorded during resting state, eyes-closed conditions characterized by quiet wakefulness, psychophysiological relaxation, and mind-wandering [39]. In cognitively healthy older adults, rsEEG alpha rhythms (8–12 Hz) predominate in the posterior scalp regions, while rsEEG delta (< 4 Hz) and theta (4–7 Hz) rhythms are typically widespread and low in amplitude [39]. Compared to Edu-Healthy individuals, Edu+ individuals exhibit higher posterior

rsEEG alpha rhythms, supporting the neuroprotective hypothesis. In contrast, Edu+ patients with AD and mild cognitive impairment show more altered posterior rsEEG alpha rhythms, consistent with the compensatory hypothesis [40]. Similar findings have been observed in older adults with subjective memory complaints who are positive for AD biomarkers, compared to Edu- controls [40, 41].

The CR hypothesis has also been tested in PD and DLB patients, yielding mixed results [42–44]. In line with findings in AD, Edu+ PD and DLB patients generally exhibit better cognitive performance, particularly in executive functions and episodic memory, and experience less cognitive decline over time, taking disease symptom severity and duration into account [43, 45–53]. The strength of these associations varies depending on the clinical subtype of the disease, the CR measure used, and disease severity (for recent reviews on CR and alpha-synucleinopathy, see [54, 55]). However, it remains less clear than in AD whether PD and DLB Edu+ compared to Edu-patients may (1) maintain a similar cognitive status against greater brain neuropathology and neurodegeneration, in line with *compensatory mechanisms*, or (2) show better cognitive status and lower brain neuropathology and neurodegeneration, in line with a sort of *neuroprotective mechanisms acting even after the onset of dementia*.

According to the hypothesis of *compensatory (resilient) mechanisms*, a positive association between educational attainment, [(11)C] PiB PET-based amyloid deposition in the brain, and cognitive status was observed in PD patients with relatively low educational attainment, ranging from cognitively unimpaired to dementia [56]. This association was not found in patients with the highest educational attainment, suggesting a CR moderation effect [55]. In that study, the level of brain amyloidosis was similar in both PD subgroups, indicating that high CR in Edu+ patients did not prevent brain amyloidosis but merely mitigated its clinical effects [56]. Another study found a positive association between CR level (measured with a questionnaire), cognitive status, and [18 F]-flutemetamol-PET-based brain amyloidosis in PD patients with cognitive deficits [57].

Similar findings were reported in DLB patients. For instance, a negative association was found between educational attainment and metabolism in temporal, parietal, and occipital areas, as revealed

by fluorine-18 fluorodeoxyglucose (FDG)-PET [58]. Another study reported a negative association between educational attainment and FDG-PET-based metabolism in occipital areas related to the degree of patient autonomy [59]. Additionally, there was a negative association between educational attainment and FDG-PET metabolism in the parietal cortex and precuneus in DLB patients [60]. Moreover, the DLB-typical diagnostic cingulate island sign was more prominent in patients with lower educational attainment [60]. Furthermore, a negative association was observed between specific occupational profiles (as CR proxies) and FDG-PET-based functional connectivity in the anterior default mode and visual cortical networks in DLB patients [52]. Finally, DLB patients with higher educational attainment exhibited stronger associations between clinical core features (e.g., parkinsonism, visual hallucinations, RBD, cognitive deficits) and specific patterns of brain hypometabolism and hypermetabolism [61].

In support of the hypothesis of *neuroprotective mechanisms even after the onset of cognitive deficits*, a positive association was reported between educational attainment and MRI-based gray matter volume in the basal ganglia of PD patients with cognitive deficits [62]. The same study also found a positive association between leisure time (another CR dimension) and gray matter volume in the dorsal prefrontal cortex [62]. Another study in PD patients with cognitive deficits reported a positive association between CR level (measured with a questionnaire), cognitive status, and FDG-PET metabolism in the right fusiform gyrus, lateral temporal, occipital, and parietal cortical areas [62]. In DLB patients, a positive association was observed between educational attainment, visual-cognitive functions, and dopamine transporter binding in the basal ganglia, as measured by 123-I-ioflupane single photon emission computed tomography (SPECT) [63].

Finally, previous studies explored the relationship between CR indices and functional connectivity in relevant brain networks. One study conducted in PD patients with cognitive deficits used resting-state functional MRI (rs-fMRI) to investigate functional brain connectivity [64]. Compared to PD Edu- patients, PD Edu+ patients exhibited greater functional connectivity in the anterior cingulate and basal ganglia, as well as bilaterally greater functional connectivity in frontoparietal regions within networks

defined by dorsolateral and ventrolateral prefrontal seeds [64]. Another study was conducted on DLB patients using FDG-PET to investigate functional brain connectivity and found a positive association between educational attainment and FDG-PET functional connectivity in executive, attentive, and posterior default mode networks [52].

The present study aimed to investigate the effect of educational attainment on rsEEG rhythms in patients with PDD and DLB. This was done to evaluate the (neuroprotective or compensatory/resilient) impact of CR on the neurophysiological mechanisms underlying the regulation of cortical arousal and vigilance in quiet wakefulness, as revealed by those rhythms. This dimension has not been extensively explored, despite its significant clinical relevance. For instance, effective vigilance regulation is essential for activities such as reading newspapers, following TV programs, and engaging in social conversations with friends and relatives [65]. Prior research has demonstrated that individuals with PDD and DLB exhibit aberrantly large rsEEG delta and theta rhythms across a multitude of regions, accompanied by a reduction in posterior rsEEG alpha rhythms [66–74]. These alterations in rsEEG rhythms have also been associated with symptoms of vigilance dysfunction, such as visual hallucinations and RBD, in PDD and DLB patients [74, 75]. The neuroprotective effect of education was tested in a control group of cognitively unimpaired older adults. This study would help to elucidate the neuroprotective and compensatory role of education in relation to neurodegenerative disease progression. There is an urgent need to determine the extent to which socio-economic status is associated with educational inequalities in brain health and to develop appropriate strategies to compensate for these inequalities.

Materials and methods

Participants

The clinical and rsEEG datasets for the present investigation were sourced from the Eurasian archive of the PDWAVES Consortium (www.pdwaves.eu) and the European DLB Consortium. These datasets comprised records from 54 Healthy, 75 PDD, and 50 DLB participants, all of whom had undergone rsEEG recordings under the eyes-closed condition.

Specifically, they were recruited by the following clinical units: the Sapienza University of Rome (Italy), the University “G. d’Annunzio” of Chieti-Pescara (Italy), the University of Salerno (Italy), the Institute for Research and Evidence-based Care (IRCCS) “Fatebenefratelli” of Brescia (Italy), the IRCCS Synlab SDN of Naples (Italy), the Oasi Research Institute-IRCCS, Troina (Italy), the IRCCS Ospedale Policlinico San Martino and DINOEMI (University of Genova, Italy), the Hospital San Raffaele of Cassino (Italy), the IRCCS San Raffaele Pisana of Rome (Italy), Newcastle University (UK), the Translational and Clinical Research Institute of Newcastle University (UK), Dokuz Eylül University, Faculty of Medicine (Izmir, Turkey), and Istanbul Medipol University (Turkey).

To assess the impact of educational attainment as a proxy of CR on the rsEEG activations, the enrolled Healthy, PDD, and DLB participants were stratified in sub-groups according to the median educational attainment of each group: Healthy-Edu- ($N = 27$; ≤ 10 years of educational attainment), Healthy-Edu+ ($N = 27$; > 10 years), PDD-Edu- ($N = 30$; < 10 years), PDD-Edu+ ($N = 45$; ≥ 10 years), DLB-Edu- ($N = 21$; < 10 years), and DLB-Edu+ ($N = 29$; ≥ 10 years). Within each group (i.e., Healthy, PDD, and DLB), the Edu- and Edu+ subgroups were matched for age, sex, and global cognitive status, ensuring that the groups shared identical mean values of age, education, and MMSE score.

The local institutional ethical committees approved the study. All experiments were conducted in accordance with the Code of Ethics of the World Medical Association (Declaration of Helsinki) and the standards established by the local institutional review boards. Informed and overt consent was obtained from each participant or caregiver prior to their participation.

Diagnostic criteria

The diagnosis of PD ($N = 75$) was based on a standard clinical assessment of tremor, rigidity, and bradykinesia [76]. As measures of severity of a motor disability, the Hoehn and Yahr stage [77] and the Unified Parkinson Disease Rating Scale-III (UPDRS III [78]) for extrapyramidal symptoms were used (unfortunately, data from the Movement Disorder Society-Sponsored Revision of the Unified Parkinson’s

Disease Rating Scale were not available). Furthermore, the diagnosis of PDD was given to patients with a history of dementia, preceded by a typical levodopa-responsive Parkinsonian motor syndrome for at least 12 months and unrelated to other pathologic conditions than PD.

The selected PDD patients did not suffer from severe tremors or dyskinesias. The PDD was diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders criteria, fourth edition (DSM-IV-TR; American Psychiatric Association). The following inclusion criteria were fulfilled: (1) diagnosis of PD as specified previously; (2) a gradual neurocognitive decline in the context of established PD reported by either the patient or a reliable informant or observed by clinicians; (3) an abnormally low score in at least one of the neuropsychological tests mentioned in the following section, as defined by performances beyond 1.5 times the SD from the mean value for age- and education-matched controls or equivalent scores for abnormality according to the manuals of the tests used; and (4) moderate to severe impairment in instrumental activities of daily living and dependency. All PDD patients were under standard long-term chronic dopaminergic treatment, and all exams were performed under the ON state.

The diagnosis of the DLB ($N = 50$) was carried out according to the mentioned consensus guidelines [6]. The clinical features of the DLB patients were detected as follows: (1) the occurrence frequency and severity of hallucinations were evaluated using item-2 of the Neuropsychiatric Inventory (NPI [79]); (2) the severity of frontal dysfunction was assessed using the Frontal Assessment Battery (FAB [80]); (3) the presence and severity of the cognitive fluctuations were determined using the Clinician Assessment of Fluctuations [66, 67]; (4) extrapyramidal signs were evaluated using the Unified Parkinson Disease Rating Scale-III (UPDRS-III [78]); and (5) the presence and absence of RBD was determined based on the minimal International Classification of Sleep Disorders criteria (1992).

Exclusion criteria for healthy seniors were (1) neurological or psychiatric diseases (previous or present), (2) the presence of a depressive episode as detected by a Geriatric Depression Scale (15-item version) score higher than 5, (3) the use of chronic psychoactive drugs, and (4) the presence of significant chronic systemic illnesses such as diabetes mellitus.

In the study participants, the performance in various cognitive domains, including language, visuospatial function, executive function/attention, and memory, was assessed using local batteries of neuropsychological tests. Specifically, for the evaluation of cognitive functions, (1) language was tested by the verbal fluency test for letters [81] and the verbal fluency test category (fruits, animals, or car trades [81]); (2) visuospatial functions were assessed by the line orientation test [82] and the face recognition test [83]; (3) executive functions and attention were evaluated by the trail-making test parts A and B [84], the Stroop test [85], and the Confusion Assessment Method (executive function part [86]); and (4) memory was tested by the digit span forward and backward [87], Oktem verbal memory test [88], and the Confusion Assessment Method (memory part [86]). Notably, each clinical unit administered one or more of the above-mentioned neuropsychological tests for each cognitive domain, according to the local protocols.

The rsEEG recordings

The rsEEG recordings were conducted using local routine professional digital EEG systems licensed for clinical applications (we used the equipment brands as a covariate in the statistical models of the present study). All rsEEG recordings were performed in the morning to minimize potential variations due to circadian rhythms. Standard instructions for the resting-state condition emphasized staying awake, psychophysically relaxed with mind wandering, and following the experimenter's requests to keep the eyes closed and open during the rsEEG recording. The experiments checked the participant's behavioral state during the EEG recordings and annotated eventual deviations and alarms.

A common electrode montage of 30 scalp exploring electrodes, placed according to the 10–10 system, characterized the EEG data recordings in all clinical units, and was used for the data analysis. These electrodes, referred to as “selected electrodes,” were positioned to cover the whole scalp (Fig. 1). The reference electrode was typically placed between Fz and Cz of the 10–20 system, and the ground electrode was in the posterior midline. To minimize the influence of the different placement of the reference electrodes, all EEG data were re-referenced to the common average for the data analysis. Electrooculographic (EOG)




Fig. 1 Electroencephalographic (EEG) electrode montage. The electrode montage included 30 scalp monopolar sensors placed following the 10–10 system (i.e., Fp1, Fp2, F7, F3, Fz, F4, F8, FT7, FC3, FCz, FC4, FT8, T7, C3, Cz, C4, T8, TP7, CP3, CPz, CP4, TP8, P7, P3, Pz, P4, P8, O1, Oz and O2). This montage was used to record the resting-state EEG (rsEEG) activity during the eyes-closed condition

activity with a standard bipolar montage was also recorded to monitor and control eye movements and blinking. As minimum standards in all clinical units, electrophysiological data allowed a bandpass filtering of 0.3–70 Hz and a sampling rate of 256 Hz.

Preliminary rsEEG data analysis

The rsEEG data were centrally analyzed by experts blinded to the participants' diagnosis by the Sapienza University of Rome unit, who were blinded to the participant's diagnosis. The recorded rsEEG data were exported as a European data format (.edf) or EEGLAB set (.set) files and then processed offline using the EEGLAB toolbox ([89]; version eeglab14_1_2b) running in the MATLAB software (Mathworks, Natick, MA, USA; version: R2014b).

During the preprocessing, the rsEEG data were divided into epochs lasting 2 s (i.e., 5 min = 150 rsEEG epochs of 2 s for each experimental condition) and subjected to offline analysis. A three-step procedure was employed to detect and remove the following items: (1) recording channels (electrodes) showing prolonged artifactual rsEEG activity due to bad electric contacts or other reasons; (2) rsEEG epochs with artifacts at recording channels characterized by

generally good signals; and (3) intrinsic components of the rsEEG epochs with artifacts.

The first step involved a visual analysis of the recorded rsEEG activity by two independent experimenters chosen from a panel of four experts (i.e., S.L., C.D.P, R.L., and G.N.). Their task was to identify electrodes affected by irremediable artifacts. Typically, up to three selected electrodes were removed for each participant. In cases where the clinical units utilized a digital EEG system with more than 30 exploring electrodes, the removed electrodes were substituted with the nearest electrodes not included among the 30 selected electrodes. These added electrodes were then used alongside the artifact-free selected electrodes to compute the interpolation of artifact-free rsEEG data at all scalp sites corresponding to the removed electrodes. This process, facilitated by the EEGLAB toolbox ([89]; version eeglab14_1_2b), ensured that all participants had artifact-free EEG data at the locations of the 30 selected electrodes.

The second step involved a visual analysis of the recorded rsEEG activity by the experimenters (i.e., S.L., C.D.P, R.L., and G.N.) to identify artifactual rsEEG epochs. These epochs were contaminated by muscular, ocular, head movements, or non-physiological artifacts and were subsequently removed from the database. Notably, muscle tension artifacts were identified through careful observation of the effects of various frequency bandpass filters and inspection of EEG power density spectra. These artifacts manifested as unusually high and stable values of EEG power density in the frequency range of 30 to 70 Hz, contrasting with the typical declining trend observed in EEG power density from 25 Hz onward.

The third step involved implementing independent component analysis (ICA) using the EEGLAB toolbox to remove components representing residual artifacts. These artifacts included (1) blinking and eye movements, (2) involuntary head movements, (3) neck and shoulder muscle tensions, and (4) electrocardiographic pulse activity. For each rsEEG dataset, less than 5 ICA components were removed from the original solutions, which were based on 30 ICA components. Subsequently, the rsEEG datasets were reconstructed with the remaining artifact-free ICA components. To ensure the integrity of the data, the putative artifact-free rsEEG epochs underwent visual double-checking by the independent experimenters (i.e., S.L., C.D.P, R.L., and G.N.).

This step confirmed or made the final decision about the inclusion or exclusion of each rsEEG epoch.

For harmonization purposes, the artifact-free EEG data for the common 30 electrodes were digitally frequency-band passed at 0.1–45 Hz. They also were down-sampled, when appropriate, to make the sampling rate of all artifact-free rsEEG datasets equal to 256 Hz. Furthermore, the EEG data were re-referenced to the common average reference.

As a result of the above procedures, the artifact-free epochs showed a similar proportion (greater than 75%) of the total amount of rsEEG activity recorded in all groups of participants (i.e., Healthy, PDD, and DLB).

Spectral analysis of the rsEEG epochs

Standard digital fast Fourier Transform (FFT)-based analysis, employing the Welch technique with a Hanning windowing function and no phase shift, was used to compute the power density of the artifact-free rsEEG epochs recorded at all 30 scalp electrodes, with a frequency resolution of 0.5 Hz.

The rsEEG frequency bands of interest were individually identified based on specific frequency landmarks, namely the transition frequency (TF) and the individual alpha frequency (IAF). In the (eyes-closed) rsEEG power density spectrum, the TF was defined as the minimum rsEEG power density between 3 and 8 Hz. In comparison, the IAF peak was defined as the maximum power density peak between 6 and 14 Hz.

The TF and IAF were computed for each participant involved in the study. Based on TF and IAF, individual delta, theta, and alpha bands were estimated as follows: delta from TF – 4 Hz to TF – 2 Hz, theta from TF – 2 Hz to TF, low alpha (alpha 1 and alpha 2) from TF to IAF, and high-frequency alpha (or alpha 3) from IAF to IAF + 2 Hz. Specifically, the individual alpha 1 and alpha 2 bands were computed as follows: alpha 1 from TF to the frequency midpoint of the TF–IAF range and alpha 2 from that midpoint to the IAF peak. The other bands were defined based on standard fixed frequency ranges used in the reference rsEEG studies of our Consortium [40, 41]: beta 1 from 14 to 20 Hz, beta 2 from 20 to 30 Hz, and gamma from 30 to 40 Hz.

Estimation of rsEEG source activation

We used the official freeware tool called exact LORETA (eLORETA) to linearly estimate the cortical source activity generating scalp-recorded rsEEG rhythms). The present implementation of the eLORETA freeware uses a head volume conductor model composed of the scalp, skull, and cerebral cortex. In the scalp compartment, the exploring electrodes can be virtually positioned to give EEG data as an input to the source estimation [90]. The cortical model is based on a realistic cerebral shape from a template typically used in neuroimaging studies, namely that of the Montreal Neurological Institute (MNI152 template). Using eLORETA, the EEG inverse problem is solved from scalp-recorded EEG activity, estimating the associated “neural” current density values at any cortical voxel within the head volume conductor model. Cortical source solutions are computed at each voxel of the model and each frequency bin.

For the estimation of EEG cortical source activities (i.e., the eLORETA solutions), the input consists of EEG spectral power density computed at the 30 scalp electrodes. This estimation occurs within the electrical cortical source space, which comprises 6239 voxels with 5 mm resolution, restricted to the cortical grey matter of the head volume conductor model. Within each voxel, an equivalent current dipole is located to represent the mean ionic currents generated by the local populations of cortical pyramidal neurons. The eLORETA package provides the Talairach coordinates, the lobe, and the Brodmann area (BA) for each voxel of the cortical model.

The eLORETA solutions from the rsEEG data were normalized by the following procedure. We averaged the eLORETA solutions across (1) all frequency bins from 0.5 to 45 Hz and (2) 6239 voxels of the cortical model to obtain the eLORETA “mean” solution. Afterward, we computed the ratio between any original eLORETA solution at a given condition/frequency-bin/voxel and the eLORETA mean solution. As a result, any original eLORETA solution at a given condition/frequency-bin/voxel changed to a normalized eLORETA solution.

In line with the general low spatial resolution of the current EEG methodological approach (i.e., 30 scalp electrodes), we performed a regional analysis of the eLORETA solutions. For this purpose, we separately collapsed the eLORETA solutions within

frontal (BAs 8, 9, 10, 11, 44, 45, 46, and 47), central (BAs 1, 2, 3, 4, and 6), parietal (BAs 5, 7, 30, 39, 40, and 43), occipital (BAs 17, 18, and 19), temporal (BAs 20, 21, 22, 37, 38, 41, and 42), and limbic (BAs 31, 32, 33, 34, 35, and 36) macro-regions (ROIs).

For the present eLORETA cortical source estimation, a frequency resolution of 0.5 Hz was used.

Main statistical analysis of rsEEG source activities: Healthy-Edu- vs. Healthy-Edu+, PDD-Edu- vs. PDD-Edu+, and DLB- Edu- vs. DLB-Edu+

A main statistical analysis was conducted using the commercial software STATISTICA 10 (StatSoft Inc., www.statsoft.com) to test the working hypothesis that the rsEEG source activities may be related to the sex in the Healthy, PDD, and DLB groups.

Three separate ANOVAs were performed (one for each group), with rsEEG source activities (i.e., regional normalized eLORETA solutions) as a dependent variable ($p < 0.05$). The ANOVAs included the factors Education (Edu- and Edu+, independent variable), Band (delta, theta, alpha 1, alpha 2, alpha 3, beta 1, beta 2, and gamma), and ROI (frontal, central, parietal, occipital, temporal, and limbic). The sex, the global cognition (MMSE), and the clinical unit were used as covariates. Post hoc comparisons were conducted using the Duncan test ($p < 0.05$).

Confirmation of the working hypothesis required two criteria to be satisfied: (1) a statistically significant ANOVA interaction involving the Education factor ($p < 0.05$) and (2) a post-hoc Duncan test revealing statistically significant ($p < 0.05$ Bonferroni corrected) differences in the rsEEG source activities between the Edu- and Edu+ subgroups.

The results of the main statistical analysis were subjected to the Grubbs test to evaluate the eventual presence of outliers ($p < 0.001$).

For cross-validation purposes, the same experimental designs were applied to a separate experimental cohort extracted from a previous database of rsEEG data. The participants were enrolled in the same clinical units with the procedure described in the previous sections. The rsEEG data were acquired with a 19-electrode montage (10–20 international system) and the same recording protocol (eyes closed and open conditions). The same rsEEG preprocessing and source activity estimation described above were applied. To reach a satisfying sample, we included

patients both at the prodromal (mild cognitive impairment, MCI) and dementia stages for PD and LB diseases. The following participants were included: Healthy ($n = 54$), PD (MCI and dementia; $N = 38$), and DLB (MCI and dementia; $N = 44$). In the Supplementary Materials Methods, we included details concerning the diagnostic procedure for MCI definition in this separate cohort. The same statistical designs were applied to evaluate the effect of educational attainment on rsEEG source activities in Healthy, PD (MCI and dementia), and DLB (MCI and dementia).

Results

Demographic, clinical, and rsEEG source markers in Healthy-Edu- and Healthy-Edu+ subgroups

Table 1 summarizes the relevant demographic (i.e., age, education, and sex) and clinical (i.e., MMSE score raw and corrected for age and education) information about the Healthy-Edu- ($N = 27$) and Healthy-Edu+ ($N = 27$) subgroups, together with the results of the statistical analyses computed to evaluate the presence or absence of statistically significant differences between these subgroups regarding age (T -test), sex (Fisher test), education (T -test), and MMSE score (raw and corrected; Mann-Whitney U test). As expected, statistically significant differences were found between the Healthy-Edu- and the Healthy-Edu+ subgroups for educational attainment ($p < 0.01$). On the contrary, no statistically significant differences in age, sex, and MMSE score (raw and corrected) were found between the two subgroups ($p > 0.05$).

The mean TF was 5.6 Hz (± 0.2 SE) in the Healthy-Edu- subgroup and 5.8 Hz (± 0.2 SE) in the Healthy-Edu+ subgroup. Furthermore, the mean IAF was 8.9 Hz (± 0.2 SE) in the Healthy-Edu- subgroup and 9.0 Hz (± 0.2 SE) in the Healthy-Edu+ subgroup. Two T -tests ($p < 0.05$) were performed to evaluate the presence or absence of statistically significant differences between the Healthy-Edu- and the Healthy-Edu+ subgroups regarding TF and IAF. No statistically significant differences were found between the two subgroups ($p > 0.05$).

Figure 2 shows the mean values (\pm SE, log-10 transformed) of rsEEG source activities (normalized eLORETA current density) relative to a statistically

Table 1 Mean values (\pm standard error of the mean, SE) of the demographic and clinical data as well as the results of their statistical comparisons ($p < 0.05$) in the subgroups of Healthy-Edu- ($N = 27$) and Healthy-Edu+ ($N = 27$) participants. Each group was partitioned into low (Edu-) and high (Edu+) educational attainment subgroups, matched for age, sex, and cog-

nitive-motor status. Legend: *Healthy*, cognitively unimpaired older persons; *M/F*, males/females; *MMSE*, Mini-Mental State Evaluation; *MMSEc*, Mini-Mental State Evaluation corrected for age and educational attainment; *n.s.*, not significant ($p > 0.05$)

Demographic and clinical data			
	Healthy-Edu-	Healthy-Edu+	Statistical analyses
<i>N</i>	27	27	–
Age (years)	68.3 \pm 1.5 SE	70.0 \pm 1.7 SE	<i>T</i> -test: n.s
Sex (M/F)	11/16 (41%)	14/13 (52%)	Fisher test: n.s
Education (years)	7.0 \pm 0.6 SE	14.0 \pm 0.5 SE	<i>T</i> -test: $p < 0.01$
MMSE score	28.4 \pm 0.4 SE	28.6 \pm 0.4 SE	Mann Whitney <i>U</i> test: n.s
MMSEc score	27.8 \pm 0.3 SE	27.3 \pm 0.3 SE	Mann Whitney <i>U</i> test: n.s

ANOVA interaction between Education group and Band in Healthy seniors

Current effect: $F(7, 343) = 4.7317, p = 0.00004$

(Sex, MMSE and Unit as covariates)




Fig. 2 Mean values (\pm standard error of the mean SE, Log-10 transformed) of rsEEG source activities (normalized eLORETA current density) relative to a statistically significant ANOVA interaction effect ($F = 4.73, p < 0.01$) between the factors Education (Healthy-Edu-, $N = 27$; and Healthy-Edu+, $N = 27$) and Band (delta, theta, alpha 1, alpha 2, alpha 3, beta 1, beta 2, and gamma). The sex, MMSE, and clinical unit were

used as a covariate. The rectangles indicate the frequency bands in which the eLORETA solutions statistically presented a significant difference between Healthy-Edu- and Healthy-Edu+ subgroups ($p < 0.05$ Bonferroni corrected). Legend: *Healthy*, cognitively unimpaired older persons; *rsEEG*, resting-state electroencephalographic

significant two-way ANOVA interaction effect ($F(7, 343) = 4.73, p < 0.01$) between the factors Education (Healthy-Edu- and Healthy-Edu+; dependent variable) and Band (delta, theta, alpha 1, alpha 2, alpha 3,

beta 1, beta 2, and gamma). The effect size was quantified by $h_p^2 = 0.09$ (medium to large effect size). The Duncan planned post hoc (p Healthy-Edu- was fitted by the rsEEG alpha 3 ($p < 0.05$).

The findings mentioned above were not due to outliers from individual normalized eLORETA current densities (Log10 transformed), as shown by Grubbs' test with an arbitrary threshold of $p > 0.001$ (See Supplementary Materials Figure SM1).

Demographic, clinical, and rsEEG source markers in PDD-Edu- and PDD-Edu+ subgroups

Table 2 summarizes the relevant demographic (i.e., age, education, and sex) and clinical (i.e., MMSE score raw and corrected for age and education, visual hallucination, VH, and Unified Parkinson Disease Rating Scale-III, UPDRS III score; REM behavioral disorder, RBD) information about the PDD-Edu- ($N = 30$) and PDD-Edu+ ($N = 45$) subgroups, together with the results of the statistical analyses computed to evaluate the presence or absence of statistically significant differences between these subgroups regarding age (T -test), sex (Fisher test), education (T -test), MMSE score (raw and corrected; Mann-Whitney U test), VH (Fisher test), UPDRS III score (T -test). As expected, statistically significant differences were found between the PDD-Edu- and PDD-Edu+ subgroups for educational attainment ($p < 0.01$). The MMSE score was higher in the PDD-Edu+ subgroup than in the PDD-Edu- subgroup ($p < 0.01$). On the contrary, no statistically significant differences in age, sex, MMSE score corrected, VH, UPDRS III score,

and RBD were found between the two subgroups ($p > 0.05$).

The mean TF was 4.5 Hz (± 0.1 SE) in the PDD-Edu- subgroup and 4.7 Hz (± 0.1 SE) in the PDD-Edu+ subgroup. Furthermore, the mean IAF was 7.2 Hz (± 0.2 SE) in the PDD-Edu- subgroup and 6.7 Hz (± 0.1 SE) in the PDD-Edu+ subgroup. Two T -tests ($p < 0.05$) were performed to evaluate the presence or absence of statistically significant differences between the PDD-Edu- and PDD-Edu+ subgroups regarding TF and IAF. No statistically significant differences were found between the two subgroups ($p > 0.05$).

Table 3 illustrates the main pharmacological therapies administered to the PDD-Edu- and PDD-Edu+ subgroups, together with the results of the statistical analyses computed to evaluate the presence or absence of statistically significant differences between these subgroups regarding the percentage of patients undergoing to a specific pharmacological treatment (Fisher test) and regarding the levodopa equivalent dose (LED, mg, T -test). No statistically significant differences were found between the PDD-Edu- and PDD-Edu+ subgroups for any pharmacological treatment nor LED ($p > 0.05$).

Figure 3 shows the mean values (\pm SE, log-10 transformed) of rsEEG source activities (normalized eLORETA current density) relative to a statistically significant two-way ANOVA interaction effect ($F(7, 490) = 3.05, p < 0.01$) between the factors Education

Table 2 Mean values (\pm SE) of the demographic and clinical data as well as the results of their statistical comparisons ($p < 0.05$) in the subgroups of PDD-Edu- ($N = 30$) and PDD-Edu+ ($N = 45$) participants. Each group was partitioned into low (Edu-) and high (Edu+) educational attainment subgroups, matched for age, sex, and cognitive-motor status. Legend:

PDD, Parkinson's disease dementia; *M/F*, males/females; *MMSE*, Mini-Mental State Evaluation; *MMSEc*, Mini-Mental State Evaluation corrected for age and educational attainment; *VH*, visual hallucination; *UPDRS III*, Unified Parkinson Disease Rating Scale-III; *RBD*, REM behavioral disorder; *n.s.*, not significant ($p > 0.05$)

Demographic and clinical data

	PDD-Edu-	PDD-Edu+	Statistical analyses
N	30	45	-
Age (years)	71.5 \pm 1.4 SE	73.3 \pm 0.8 SE	T -test: n.s
Sex (M/F)	25/5 (83%)	37/8 (82%)	Fisher test: n.s
Education (years)	3.6 \pm 0.4 SE	10.9 \pm 0.2 SE	T -test: $p < 0.01$
MMSE score	18.1 \pm 0.7 SE	21.0 \pm 0.7 SE	Mann Whitney U test: $p < 0.01$
MMSEc score	18.1 \pm 0.7 SE	19.8 \pm 0.7 SE	Mann Whitney U test: n.s
VH (%)	53%	56%	Fisher test: n.s
UPDRS III	39.6 \pm 3.8 SE	41.3 \pm 3.0 SE	T -test: n.s
RBD (%)	53%	53%	Fisher test: n.s
Disease duration (years)	8.3 \pm 1.4 SE	3.6 \pm 0.8 SE	T -test: $p < 0.01$

Table 3 Pharmacological therapies administered to the PDD-Edu- and PDD-Edu+ subgroups. Legend: *PDD*, Parkinson's disease dementia; *n.s.*, not significant ($p > 0.05$)

Drugs	PDD-Edu-		PDD-Edu+		Statistical analysis
	<i>N</i>	%	<i>N</i>	%	
High blood pressure drugs	3	10%	6	13%	Fisher test = n.s
Diabetes drugs	2	7%	6	13%	Fisher test = n.s
Selective serotonin reuptake inhibitors (SSRIs)	5	17%	4	9%	Fisher test = n.s
Anxiolytics	0	0%	3	7%	Fisher test = n.s
Antipsychotics	4	13%	4	16%	Fisher test = n.s
Antagonists of N-methyl-d-aspartate receptors (aNMDARs)	6	20%	5	11%	Fisher test = n.s
Acetylcholinesterase inhibitors (AChEIs)	7	23%	16	36%	Fisher test = n.s
Antiparkinsonian drugs (levodopa)	29	97%	44	98%	Fisher test = n.s
	Mean ± SE		Mean ± SE		
Levodopa equivalent dose (LED; mg)	608.3 ± 76.0		606.3 ± 48.3		<i>T</i> -test = n.s

ANOVA interaction between Education group and Band in PDD patients

Current effect: $F(7, 490) = 3.0418, p = 0.00385$

(Sex, MMSE and Unit as covariates)




Fig. 3 Mean values (\pm SE, Log-10 transformed) of rsEEG source activities (normalized eLORETA current density) relative to a statistically significant ANOVA interaction effect ($F = 3.04, p < 0.01$) between the factors Education (PDD-Edu-, $N = 30$, and PDD-Edu+, $N = 45$) and Band (delta, theta, alpha 1, alpha 2, alpha 3, beta 1, beta 2, and gamma). The sex, MMSE,

and clinical unit were used as a covariate. The rectangles indicate the frequency bands in which the eLORETA solutions statistically presented a significant difference between PDD-Edu- and PDD-Edu+ ($p < 0.05$ Bonferroni corrected). Legend: *PDD*, Parkinson's disease dementia; *rsEEG*, resting-state electroencephalographic

(PDD-Edu- and PDD-Edu+; dependent variable) and Band (delta, theta, alpha 1, alpha 2, alpha 3, beta 1, beta 2, and gamma). The effect size was quantified by $\eta_p^2 = 0.09$ (medium to large effect size). The Duncan planned post hoc ($p < 0.05$ Bonferroni correction for 8 frequency bands, $p < 0.05/8 = 0.006$) testing showed that the discriminant pattern PDD-Edu- > PDD-Edu+ was fitted by the rsEEG alpha 3 ($p < 0.05$ Bonferroni corrected) source activity. No other effects involving the factor of Education were observed ($p > 0.05$).

The findings mentioned above were not due to outliers from individual normalized eLORETA current densities (Log10 transformed), as shown by Grubbs' test with an arbitrary threshold of $p > 0.001$ (See Supplementary Materials Figure SM2).

Demographic, clinical, and rsEEG source markers in DLB-Edu- and DLB-Edu+ subgroups

Table 4 summarizes the relevant demographic (i.e., age, education, and sex) and clinical (i.e., MMSE score raw and corrected for age and education, visual hallucination, VH, and Unified Parkinson Disease Rating Scale-III, UPDRS III score; REM behavioral disorder, RBD) information about the DLB-Edu- ($N = 21$) and DLB-Edu+ ($N = 29$) subgroups, age (T -test), sex (Fisher test), education (T -test), MMSE score (raw and corrected; Mann-Whitney U test),

VH (Fisher test), and UPDRS III score (T -test). As expected, statistically significant differences were found between the DLB-Edu- and DLB-Edu+ subgroups for educational attainment ($p < 0.01$). On the contrary, no statistically significant differences in age, sex, MMSE score (raw and corrected), VH, UPDRS III score, and RBD were found between the two subgroups ($p > 0.05$).

The mean TF was 4.7 Hz (± 0.2 SE) in the DLB-Edu- subgroup and 4.8 Hz (± 0.2 SE) in the DLB-Edu+ subgroup. Furthermore, the mean IAF was 7.6 Hz (± 0.3 SE) in the DLB-Edu- subgroup and 7.0 Hz (± 0.2 SE) in the DLB-Edu+ subgroup. Two T -tests ($p < 0.05$) were performed to evaluate the presence or absence of statistically significant differences between the DLB-Edu- and DLB-Edu+ subgroups regarding TF and IAF. No statistically significant differences were found between the two subgroups ($p > 0.05$).

Table 5 illustrates the main pharmacological therapies administered to the DLB-Edu- and DLB-Edu+ subgroups, together with the results of the statistical analyses computed to evaluate the presence or absence of statistically significant differences between these subgroups regarding the percentage of patients undergoing to a specific pharmacological treatment (Fisher test) and regarding the levodopa equivalent dose (LED, mg, T -test). No statistically significant differences were found between the DLB-Edu- and DLB-Edu+ subgroups for any pharmacological

Table 4 Mean values (\pm SE) of the demographic and clinical data as well as the results of their statistical comparisons ($p < 0.05$) in the subgroups of DLB-Edu- ($N = 21$) and DLB-Edu+ ($N = 29$) participants. Each group was partitioned into low (Edu-) and high (Edu+) educational attainment subgroups, matched for age, sex, and cognitive-motor status. Leg-

end: *DLB*, dementia due to Lewy body disease; *M/F*, males/females; *MMSE*, Mini-Mental State Evaluation; *MMSEc*, Mini-Mental State Evaluation corrected for age and educational attainment; *VH*, visual hallucination; *UPDRS III*, Unified Parkinson Disease Rating Scale-III; *RBD*, REM behavioral disorder; *n.s.*, not significant ($p > 0.05$)

Demographic and clinical data

	DLB-Edu-	DLB-Edu+	Statistical analyses
<i>N</i>	21	29	-
Age (years)	74.0 \pm 1.8 SE	75.1 \pm 1.6 SE	T -test: n.s
Sex (M/F)	12/9 (41%)	23/6 (79%)	Fisher test: n.s
Education (years)	5.0 \pm 0.5 SE	11.5 \pm 1.3 SE	T -test: $p < 0.01$
MMSE score	19.1 \pm 1.3 SE	21.6 \pm 0.8 SE	Mann Whitney U test: n.s
MMSEc score	18.8 \pm 1.3 SE	20.2 \pm 0.9 SE	Mann Whitney U test: n.s
VH (%)	76%	62%	Fisher test: n.s
UPDRS III	13.5 \pm 1.6 SE	15.8 \pm 1.4 SE	T -test: n.s
RBD (%)	75%	57%	Fisher test: n.s
Disease duration (years)	1.1 \pm 0.4 SE	2.3 \pm 0.4 SE	T -test: $p < 0.05$

Table 5 Pharmacological therapies administered to the DLB-Edu- and DLB-Edu+ subgroups. Legend: *DLB*, dementia due to Lewy body disease; *n.s.*, not significant ($p > 0.05$)

Drugs	DLB-Edu-		DLB-Edu+		Statistical analysis
	<i>N</i>	%	<i>N</i>	%	
High blood pressure drugs	6	29%	12	41%	Fisher test = n.s
Diabetes drugs	8	38%	12	41%	Fisher test = n.s
Selective serotonin reuptake inhibitors (SSRIs)	10	48%	8	28%	Fisher test = n.s
Anxiolytics	0	0%	1	3%	Fisher test = n.s
Antipsychotics	5	24%	3	10%	Fisher test = n.s
Antagonists of N-methyl-d-aspartate receptors (aNMDARs)	2	10%	1	3%	Fisher test = n.s
Acetylcholinesterase inhibitors (AChEIs)	16	76%	26	90%	Fisher test = n.s
Antiparkinsonian drugs (levodopa)	11	52%	13	45%	Fisher test = n.s
	Mean ± SE		Mean ± SE		
Levodopa equivalent dose (LED; mg)	261.5 ± 38.0		153.5 ± 22.0		T test = $p < 0.01$

treatment ($p > 0.05$). On the contrary, a statistically significant difference was found between the two subgroups for LED ($p < 0.01$). The LED was higher in the DLB-Edu- subgroup than in the DLB-Edu+ subgroup ($p < 0.01$). Due to this difference, the LED was included as a covariate in the following statistical analysis.

The ANOVA did not show any statistically significant three- or two-way interaction effect ($p > 0.05$) between the factors Education (DLB-Edu- and DLB-Edu+; dependent variable), Band (delta, theta, alpha 1, alpha 2, alpha 3, beta 1, beta 2, and gamma), and ROI (frontal, central, parietal, occipital, temporal, and limbic).

The findings mentioned above were not due to outliers from individual normalized eLORETA current densities (log 10 transformed), as shown by Grubbs' test with an arbitrary threshold of $p > 0.001$ (See Supplementary Materials Figure SM3).

For illustrative purposes, Figure 4 shows the mean values (\pm SE, log-10 transformed) of rsEEG source activities (normalized eLORETA current density) in relation to the factors Education (DLB-Edu- and DLB-Edu+), Band (delta, theta, alpha 1, alpha 2, alpha 3, beta 1, beta 2, and gamma), and ROI (frontal, central, parietal, occipital, temporal, and limbic). Very similar rsEEG alpha source activities were observed between the DLB-Edu- and DLB-Edu+ groups ($p > 0.05$). Furthermore, figures reported in the Supplementary Materials illustrate the topographic and frequency distribution of the

rsEEG alpha 2 and alpha 3 source activities for all the Healthy (Figure SM4) and PDD (Figure SM5) Edu- and Edu+ subgroups.

Control analysis on the effect of participants' linguistic-cultural background

A control analysis tested the effect of the participants' linguistic-cultural background as a factor on the relationship between educational attainment and rsEEG rhythms in the Healthy, DLB, and PDD groups. Based on the limited composition of the available cohort, we could only form two subgroups of participants for that factor, namely European (Italy and the UK) and Turkish. Specifically, for each group of participants (Healthy, DLB, and PDD), the control ANOVA ($p < 0.05$) included the factors of Linguistic-cultural background (Europe and Turkey), Education (Edu- and Edu+), Band (delta, theta, alpha 1, alpha 2, alpha 3, beta 1, beta 2, gamma), and ROI (frontal, central, parietal, occipital, temporal, and limbic). Results showed no effect of the linguistic-cultural background factor ($p > 0.05$). Furthermore, they confirmed a two-way interaction ($p > 0.05$) between Education (Edu-, Edu+) and Band (delta, theta, alpha 1, alpha 2, alpha 3, beta 1, beta 2, gamma) for all the groups as in the core findings (i.e., Healthy, DLB, and PDD groups). We reported the details of this control analysis in the Supplementary Materials (Figure SM6).

Topographic and frequency distribution of rsEEG source activities in DLB patients




Fig. 4 Mean values (\pm standard error of the mean SE, Log-10 transformed) of rsEEG source activities (normalized eLORETA current density) in DLB participants according to the factors Education (DLB-Edu- and DLB-Edu+; dependent variable), Band (delta, theta, alpha 1, alpha 2, alpha 3, beta 1, beta 2, and gamma), and ROI (frontal, central, parietal, occipital,

temporal, and limbic). The correspondent ANOVA was not statistically significant for the 3-way interaction among the factors Education, Band, and ROI ($p > 0.05$). The sex, clinical unit, and LED were used as a covariate. Legend: DLB, dementia due to Lewy body disease; rsEEG, resting state electroencephalographic; ROI, region of interest

Control analysis matching the educational attainment threshold defining the low and high-education sub-groups within the Healthy, DLB, and PDD participants

A control analysis ($p < 0.05$) tested the effect of possible bias due to the different thresholds used to stratify the low (Edu-) and high (Edu+) education subgroups in the Healthy, DLB, and PDD groups of the main statistical analysis. For this purpose, this analysis matched the educational attainment levels of the Edu- and Edu+ subgroups across the Healthy, DLB, and PDD participants. For each subgroup of participants (Healthy, DLB, and PDD), the control ANOVA ($p < 0.05$) included the factors of Education (Edu- and Edu+), Band (delta, theta, alpha 1, alpha 2, alpha 3, beta 1, beta 2, gamma), and ROI (frontal, central, parietal, occipital, temporal, and limbic). Results confirmed those obtained on the whole cohort, showing that the discriminant pattern Healthy-Edu+ > Healthy-Edu- was fitted by the rsEEG alpha 3 ($p < 0.05$ Bonferroni corrected) source activities. On the contrary, the discriminant pattern PDD-Edu- > PDD-Edu+ was fitted by the rsEEG alpha 2 and alpha 3 ($p < 0.05$ Bonferroni corrected)

source activities. No statistically significant effects were observed for the DLB group ($p > 0.05$). We reported the details of this control analysis in the Supplementary Materials (Figure SM7).

Association among CR, rsEEG alpha 2 and alpha 3 source activities, and cognitive scores in Healthy, PDD, and DLB patients

The main ANOVA results showed that rsEEG alpha 2 and alpha 3 source activities were affected by the education attainment in the Healthy participants and the PDD patients. Furthermore, they showed that these alpha source activities were greater in the Healthy-Edu+ subgroup than in the Healthy-Edu- subgroup, possibly because of the effect of neurophysiological neuroprotective mechanisms. In contrast, these alpha source activities were lower in the PDD-Edu+ subgroup than in the PDD-Edu- subgroup, possibly because of the effect of compensatory mechanisms. To control for these findings and explore the relationship between the rsEEG alpha source activity and cognitive functions in Healthy, DLB, and PDD participants, we performed the following control analyses using regressive models.

Association between the rsEEG alpha source activity and MMSE in Healthy, PDD, and DLB patients

To underline the clinical relevance of rsEEG alpha rhythms, as a control analysis, a Spearman test ($p < 0.05$) evaluated the correlation between the MMSE score, as an index of the global cognitive status, and the rsEEG alpha 2 and alpha 3 source activity.

Firstly, we performed a correlation analysis considering all Healthy, PDD, and DLB individuals as a whole group for two reasons. On the one hand, the hypothesis was that rsEEG alpha source activity may correlate with the global cognitive status of seniors, including cases with both normal and impaired cognitive functions. On the other hand, the correlation study would have had a low statistical sensitivity if performed only in the separate groups, owing to the limited scatter of global composite cognitive scores within a given group.

Figure 5 illustrates the scatterplot showing the statistically significant positive correlation between the MMSE score and the posterior rsEEG (eLORETA) alpha 2 and alpha 3 source activity in all Healthy, DLB, and PDD participants (i.e., Healthy + ADD + PDD) as a whole group. The higher the posterior rsEEG (eLORETA) alpha 2 and alpha 3 source activity, the higher the MMSE score.

Secondly, we evaluated whether any statistically significant difference in the association between the rsEEG alpha source activity and MMSE depending on the Group (Healthy, DLB, and PDD) and Education (Edu-, Edu+) factors may occur. To this aim, several regression models were developed with the following design.

- Target variable: MMSE.
- Predictors: Group (Healthy, DLB, PDD), Education (Edu-, Edu+), posterior rsEEG alpha 2 and alpha 3 source activities, and their interaction.

Correlation between rEEG alpha2 and alpha 3 source activities and global cognition (MMSE)




Fig. 5 Scatterplot showing the (positive) linear Spearman test correlation between (1) the posterior (parietal, occipital, temporal, and limbic) rsEEG (eLORETA) alpha 2 and alpha

3 source activity and (2) the Mini-Mental State Evaluation (MMSE) score. This correlation was computed in all participants of the present study ($N = 179$)

- Covariates: Age, Sex, Unit.

The model accuracy was assessed by evaluating the residual standard error (RSE) and adjusted R -squared (R^2). The residuals' distribution was checked for heteroscedasticity, normality, and influential observations in the data ($p < 0.05$). The post hoc analysis was performed through the false discovery rate (FDR) correction ($p < 0.05$).

No statistically significant interaction between Group and Education was observed in the association between rsEEG alpha source activity and MMSE ($p > 0.05$).

Association between the rsEEG alpha source activity and cognitive functions in PDD patients as a function of educational attainment

To test whether the observed effect in the PDD group may effectively reflect a compensatory effect of the educational attainment (as a proxy of CR), we checked for the association among the educational attainment, the rsEEG alpha 2 and alpha 3 source activities, and the composite cognitive scores computed from the neuropsychological tests, as well as MMSE as a measure of the global cognitive status. To this aim, we computed composite cognitive scores, tested their differences between the control and experimental groups, and performed the mentioned regression analysis.

Table 6 Results of the statistical non-parametric Kruskal–Wallis H tests on the cognitive scores among the Healthy, PDD, and DLB groups. The multiple comparisons z -value was used for post hoc analysis ($p < 0.05$). Legend: *Healthy*, cog-

The composite cognitive scores were calculated as z -scores in relation to the values of the Healthy group in the following cognitive domains: language, visuospatial, attention/executive, memory, and global (average among the previous ones) functions. Figure SM8 reports the individual values of the composite cognitive scores, as well as MMSE, for each Edu- and Edu+ subgroup of Healthy, PDD, and DLB participants.

We performed a non-parametric one-way Kruskal–Wallis H test to evaluate the effect of the Group (Healthy, PDD, DLB) factor on each composite cognitive score and MMSE ($p < 0.05$). The multiple comparisons z -value test was used for post-hoc analysis ($p < 0.05$). Table 6 illustrates the results of these statistical comparisons among the Healthy, PDD, and DLB groups. As expected, a statistically significant effect of the factor Group was observed in all the composite cognitive scores, with the patients (PDD and DLB) performing worse than Healthy participants ($p < 0.01$). No statistically significant differences were observed between PDD and DLB groups ($p > 0.05$).

Several linear regression models were performed with the R software (<https://www.r-project.org/>) with the following design.

- Target variable: the cognitive score (e.g., language, visuospatial, attention/executive, memory, global, and MMSE).

natively unimpaired older persons; *PDD*, Parkinson's disease dementia; *DLB*, dementia due to Lewy body disease; *n.s.*, not significant ($p > 0.05$)

Cognitive scores			Nold vs. DLB	Nold vs. PDD	DLB vs. PDD
Language	H (2, 176) = 88.3 $p < 0.01$	Nold > DLB, PDD	$p < 0.01$	$p < 0.01$	n.s
Visuospatial functions	H (2, 121) = 43.4 $p < 0.01$	Nold > DLB, PDD	$p < 0.01$	$p < 0.01$	n.s
Attention/executive functions	H (2, 136) = 57.0 $p < 0.01$	Nold > DLB, PDD	$p < 0.01$	$p < 0.01$	n.s
Memory	H (2, 177) = 89.5 $p < 0.01$	Nold > DLB, PDD	$p < 0.01$	$p < 0.01$	n.s
Global composite score	H (2, 177) = 99.6 $p < 0.01$	Nold > DLB, PDD	$p < 0.01$	$p < 0.01$	n.s
MMSE	H (2, 177) = 101.0 $p < 0.01$	Nold > DLB, PDD	$p < 0.01$	$p < 0.01$	n.s

- Predictors: Education (PDD-Edu-, PDD-Edu+), posterior rsEEG alpha 2 and alpha 3 source activities, and their interaction.
- Covariates: Age, Sex, Unit.

The model accuracy was assessed by evaluating the residual standard error (RSE) and adjusted R -squared (R^2). The residuals' distribution was checked for heteroscedasticity, normality, and influential observations in the data ($p < 0.05$). The post-hoc analysis was performed through the false discovery rate (FDR) correction ($p < 0.05$).

Table 7 illustrates the results of the regression analysis. Only for the attention/executive function scores, a statistically significant interaction between the Education predictor and the occipital rsEEG alpha 3 and limbic rsEEG alpha 2 source activities was observed ($p < 0.05$).

As depicted in Figure 6, the post hoc analyses revealed that only the PDD-Edu- subgroups showed statistically significant positive associations between the attention/executive function score and (i) occipital rsEEG alpha 3 source activities (trend = 10.25 ± 3.83 standard error, SE; lower confidence limit = 2.54; upper confidence limit = 17.95, $p < 0.01$) and (ii) limbic rsEEG alpha 2 source activities (trend = 23.4 ± 9.09 standard error, SE; lower confidence limit = 5.06; upper confidence limit = 41.7, $p < 0.01$). No statistically significant association was observed for the PDD-Edu+ subgroup ($p > 0.05$).

Table 7 Results of the linear regression model showing the effect on the attention/executive function score (target variable) of the Education, the occipital rsEEG alpha 3 (A3 O) and the limbic rsEEG alpha 2 (A2 L), and their interaction (predictors)

Model	Predictors	β (\pm SE)	p -value
Attention ~ Edu group * A3 O + Age + Unit + Sex Multiple $R^2 = 0.3667$ Adjusted $R^2 = 0.2841$ F-statistic (6, 46) = 4.44 RSE = 4.42 p -value = 0.001272	(Intercept)	- 2.47 (\pm 5.48)	n.s
	Education	9.33 (\pm 2.90)	$p < 0.01$
	A3 O	10.25 (\pm 3.83)	$p < 0.01$
	Education * A3 O	- 10.25 (\pm 4.83)	$p < 0.05$
Attention ~ Edu group * A2 L + Age + Unit + Sex Multiple $R^2 = 0.3606$ Adjusted $R^2 = 0.2772$ F-statistic (6, 46) = 4.44 RSE = 4.33 p -value = 0.001539	(Intercept)	- 5.99 (\pm 6.08)	n.s
	Education	13.59 (\pm 4.62)	$p < 0.01$
	A3 O	23.36 (\pm 9.09)	$p < 0.01$
	Education * A2 L	- 22.07 (\pm 10.60)	$p < 0.05$

Association between the education attainment and rsEEG alpha source activities in the Healthy, PDD, and DLB participants

Several linear regression models were performed with the R software in each group of interest (i.e., Healthy, PDD, and DLB) with the following design:

- Target variable: global rsEEG alpha 2 source activity, global rsEEG alpha 3 source activity, occipital rsEEG alpha 2 source activity, or occipital rsEEG alpha 3 source activity.
- Predictor: Education attainment (years) as a continuous variable.
- Covariates: Age, sex, and recording unit.

The model accuracy was assessed by evaluating the residual standard error (RSE) and adjusted R -squared (R^2). The residuals' distribution was checked for heteroscedasticity, normality, and influential observations in the data ($p < 0.05$).

The results are reported in the following:

In the Healthy group, there were statistically significant *positive* associations between Education attainment and the following rsEEG variables: occipital alpha 3 (trend = 0.015 ± 0.008 SE; $p < 0.05$), global alpha 2 (trend = 0.010 ± 0.005 SE; $p < 0.05$), and alpha 3 source activities (trend = 0.015 ± 0.005 SE; $p < 0.01$), in line with the possible effect of neurophysiological neuroprotective mechanisms.

in the PDD group. The age, sex, and the clinical unit were used as covariates. Legend: *PDD*, Parkinson's disease dementia; *rsEEG*, resting state electroencephalographic; *RSE*, residual standard error; *n.s.*, not significant ($p > 0.05$)

Association between attention/executive function score and rsEEG alpha source activities in PDD patients




Fig. 6 Plot of the association between the attention/executive function score (estimated marginal means) and occipital/limbic rsEEG alpha 3 source activities in the PDD-Edu- and PDD-Edu+ subgroups, as revealed by the linear regression model. Only for the PDD-Edu- subgroup, there were statistically significant positive associations between the attention/executive function score and (upper graph) occipital rsEEG alpha 3 source activities (trend = 10.25 ± 3.83 standard error, SE; lower confidence limit = 2.54; upper confidence limit

= 17.95, $p < 0.01$; FDR corrected), and (lower graph) limbic rsEEG alpha 2 source activities (trend = 23.4 ± 9.09 standard error, SE; lower confidence limit = 5.06; upper confidence limit = 41.7, $p < 0.01$; FDR corrected). No statistically significant association was observed for the PDD-Edu+ subgroup ($p > 0.05$). In the model, the age, sex, and the clinical unit were used as covariates. Legend: *PDD*, Parkinson's disease dementia; *rsEEG*, resting-state electroencephalographic

In the PDD group, there were statistically significant *negative* associations between Education attainment and the following rsEEG variables: occipital alpha 2 (trend = -0.015 ± 0.005 SE; $p < 0.01$), occipital alpha 3 (trend = -0.014 ± 0.003 SE; $p <$

0.05), and global alpha 2 (trend = -0.014 ± 0.003 SE; $p < 0.01$) source activities, in line with the possible effect of compensatory mechanisms.

No statistically significant effect was found in the DLB participants ($p > 0.05$).

Cross-validation on other cohorts of Healthy, PD with cognitive deficits, and LB with cognitive deficits

In the Supplementary Materials Results, we reported the demographical and clinical information about the Healthy ($n = 54$; Table SM1), PD with cognitive deficits (mild cognitive impairment, MCI, and dementia, PDCD; $N = 38$; Table SM2), and LB with cognitive deficits (LBCD; $N = 44$; Table SM3) participants from an independent database for cross-validation purposes. In that database, inclusion/exclusion criteria and the clinical-neuropsychological protocol were quite similar to those of the main experiment. Furthermore, the rsEEG recordings were performed with 19 scalp electrodes placed according to a 10–20 montage system and the same recording protocol. The same rsEEG analysis was performed.

Briefly, similar patterns of the statistical differences between low (Edu-) and high (Edu+) educational attainment subgroups observed in the main analyses were found. In Healthy participants, there was a statistically significant ANOVA interaction effect ($F(7, 343) = 3.1610, p < 0.01$) between the factors Education (Healthy-Edu- and Healthy-Edu+; dependent variable) and Band (delta, theta, alpha 1, alpha 2, alpha 3, beta 1, beta 2, and gamma). The Duncan planned post-hoc ($p < 0.05$ Bonferroni correction for 7 frequency bands, $p < 0.05/7 = 0.007$) test showed that the discriminant pattern Healthy-Edu+ > Healthy-Edu- was fitted by the rsEEG alpha 2 and alpha 3 ($p < 0.05$ Bonferroni corrected) source activities. No other effects involving the factor Education were observed ($p > 0.05$; Figure SM8).

Along the same line, in the PDCD group, a statistically significant ANOVA interaction effect ($F(7, 490) = 3.05, p < 0.01$) between the factors Education (PDCD-Edu- and PDCD-Edu+; dependent variable) and Band (delta, theta, alpha 1, alpha 2, alpha 3, beta 1, beta 2, and gamma). The Duncan planned post hoc ($p < 0.05$ Bonferroni correction for 7 frequency bands, $p < 0.05/7 = 0.007$) testing showed that the discriminant pattern PDCD-Edu- > PDCD-Edu+ was fitted by the rsEEG alpha 2 source activity ($p < 0.05$ Bonferroni corrected). No other effects involving the factor Education were observed ($p > 0.05$; Figure SM9).

Finally, no statistically significant two- and three-way ANOVA interaction effects were observed in the DLCD group ($p > 0.05$).

Control analysis on the correlation between motor impairment and rsEEG source activities

To evaluate whether the compensatory mechanism revealed by rsEEG rhythms in the PDD group may depend on motor dysfunctions, we explored the correlation between motor impairment (UPDRS III) and rsEEG theta and alpha source activities. The theta band was included as associated with greater motor impairment in PD patients when recorded from sensorimotor cortical areas [91].

To this aim, we developed several Pearson's correlation models between the UPDRS III score and the regional (frontal, central, parietal, occipital, and temporal) and global rsEEG theta, alpha 2, and alpha 3 source activities estimated in the PDD and DLB groups. To include as many patients as possible, we pulled together the experimental and the cross-validation cohort. For the sake of simplicity, we will use the abbreviations PDD and DLB even if the cross-validation cohort was composed of patients with MCI and dementia. The results of these analyses are reported in the Supplementary Materials. Only for the extended PDD group ($N = 104$) statistically significant positive correlations were observed between the regional and global rsEEG theta source activities and the UPDRS III score; Pearson's r ranged between 0.19 and 0.30 ($p < 0.05$; Figure SM11). No statistically significant correlations were observed for the extended DLB group ($N = 83$; $p > 0.05$; Figure SM12). Concerning rsEEG alpha 2 and alpha 3 source activities, no statistically significant correlations with the UPDRS III score were observed for the extended PDD (Table SM5) and DLB (Table SM6) groups.

Discussion

In this study, we explored the relationship between educational attainment, a CR proxy, and rsEEG source activity in patients with PDD and DLB. Our goal was to evaluate the potential neuroprotective, still acting even after the onset of cognitive deficits, and compensatory (resilient) mechanisms that could influence this activity, which is crucial for the regulation of cortical arousal and vigilance during quiet wakefulness [39].

Our findings in cognitively unimpaired older adults, who served as a control group, showed that

those with higher educational attainment exhibited significantly greater rsEEG alpha source activity compared to those with lower educational attainment. These results are consistent with previous studies by our Consortium using similar methodologies [39–41] and to role played by the early-life education in protecting brain health and preventing the onset of age-related cognitive decline. This increased rsEEG alpha activity may reflect CR-dependent neuroprotective mechanisms that enhance the brain's alpha-frequency neuronal oscillations, potentially supporting cortical arousal and vigilance regulation.

A novel aspect of our study is the observation that PDD patients with higher educational attainment demonstrated lower rsEEG alpha source activity, indicative of vigilance dysregulation. Yet, they maintained a similar cognitive status to PDD patients with lower educational attainment. This effect could not be attributed to age, sex, or overall cognitive-motor status, suggesting the involvement of CR-dependent compensatory (resilient) mechanisms for cognitive status against a greater derangement of neural systems generating rsEEG alpha rhythms in patients with higher educational attainment, as previously observed in Alzheimer's disease (AD) patients [39–41]. This hypothesis is further supported by the positive correlation between rsEEG alpha source activity and attention/executive function scores in PDD patients with lower educational attainment, a relationship not observed in those with higher educational attainment, possibly due to CR's mediating role. However, the complex interplay of CR with genetic, neuropathological, neurodegenerative, sociocultural, environmental, and other factors remains unclear at the present early stage of the research.

A speculative model explaining more abnormal rsEEG alpha rhythms in PDD patients with higher educational attainment

Nearly a century after Hans Berger discovered human rsEEG alpha rhythms [92], the following previous EEG and fMRI studies suggest that the neuroprotective and compensatory mechanisms inferred from our rsEEG findings in healthy controls and PDD patients may involve reciprocal thalamic-cortical circuits, subcortical ascending systems, and cortical neural networks responsible for generating EEG activity. Specifically, previous EEG and fMRI findings in

healthy individuals indicated that dominant rsEEG alpha rhythms might reflect tonic inhibition in posterior cortical regions, primarily mediated by cortico-cortical and reciprocal cortico-thalamic circuits [39, 93–97]. Additionally, these studies found that highly educated individuals exhibited enhanced functional coupling of widespread rsEEG alpha rhythms [98, 99] and stronger associations between posterior rsEEG alpha rhythms and rs-fMRI connectivity along thalamic and visual circuits [41]. Thus, it is plausible that higher educational attainment in healthy older persons is associated with neurophysiological neuroprotective mechanisms that enhance these circuits, supporting cortical arousal and vigilance regulation.

In contrast, our findings of reduced rsEEG alpha rhythms in PDD patients with higher educational attainment may be due to a disruption of critical subcortical and cortical circuits with some compensatory (resilient) mechanisms able to compensate for it and maintain cognitive status in relation to PDD patients with lower education attainment. Previous EEG and neuroimaging studies have attributed the slowing of rsEEG alpha rhythms and the dominance of theta and delta rhythms (< 6 Hz) in patients with AD, PDD, and DLB to diminished inputs from cholinergic, noradrenergic, and dopaminergic arousal systems [39, 66–75]. For instance, posterior rsEEG alpha rhythms in AD patients were modulated by both acute [100] and chronic [101] administration of acetylcholinesterase inhibitors and noradrenergic deficits in the thalamus [102]. In PD patients with cognitive decline, rsEEG alpha rhythms and motor performance were influenced by levodopa treatment [103–105]. Furthermore, these patients exhibited a negative correlation between occipital rsEEG alpha frequency and [11 C] yohimbine PET, reflecting α_2 adrenoceptor density in the thalamus [106].

Previous studies also suggest that PDD patients with higher educational attainment may compensate (be resilient) for the disruption of cholinergic, noradrenergic, and dopaminergic systems through several structural and functional neuroprotective mechanisms that partially preserve cognitive status. These mechanisms include relatively preserved MRI-based gray matter volume in the basal ganglia and dorsal prefrontal cortex [62], FDG-PET metabolism in the right fusiform gyrus and other cortical areas [57], dopamine transporter binding in the basal ganglia [63], and rs-fMRI functional connectivity in

the anterior cingulate, basal ganglia, and frontoparietal regions [64]. Additionally, studies in PD patients with cognitive deficits have shown associations between impaired executive function, rsEEG slowing, and reduced [18 F]FDOPA PET uptake, as well as reduced gray matter volume in the cholinergic basal forebrain nuclei [107, 108].

Another interesting aspect worth discussing is that the disease duration was shorter in the PDD patients with higher than lower educational attainment. Indeed, the PDD-Edu+ subgroup was characterized by a delayed disease onset, followed by a more accelerated cognitive and functional decline. This is in line with previous evidence that higher education delays the onset of degenerative diseases in aging, possibly due to neuroprotective processes of cognitive reserve [108]. However, this delay is not necessarily related to a lower neuropathological burden (i.e., brain amyloidosis), so the cognitive decline may be faster when the cognitive reserve is exhausted [38, 57].

Unfortunately, we lack structural and functional neuroimaging data to fully understand why the rsEEG activity in DLB patients did not differ with educational attainment levels. We can only speculate that in the present cohorts, the DLB patients with higher educational attainment may have exhausted the CR-related compensatory mechanisms due to heavier neuropathological and neurodegenerative burdens with eventual implications on cholinergic systems than those possibly affecting PDD patients. In this speculative line, previous neuroimaging studies in DLB patients have shown significant negative associations between CR indices and FDG-PET metabolism in key brain regions [58–60], as well as between CR indices and functional connectivity in cortical networks associated with core clinical features of DLB [52, 61]. Furthermore, they often reported heavy co-pathologies in DLB compared to PDD patients, such as AD-related neurofibrillary tangles and A β plaques [109–112] or frontotemporal lobar degeneration (FTLD [113]). Moreover, DLB patients were found to be characterized by more severe neuronal loss and the predominant involvement of the medial portion of the substantia nigra (which projects to the caudate nucleus) as compared to PDD patients [114]. Finally, meta-analyses revealed more beneficial clinical effects of cholinesterase inhibitors in PDD patients, possibly reflecting more responsiveness of residual cholinergic neurons than in DLB patients

[115, 116]. The disruptive effect of the burden of these co-pathologies may also lead to more rapid cognitive decline over time [112], possibly reducing the time for CR to induce neuroplasticity and reorganization of brain functional connectivity to maintain cognitive status. This would be consistent with the shorter disease duration of the DLB compared to the PDD observed in the present study cohort, suggesting a more aggressive and rapid neurodegenerative phenomenon. Future longitudinal data collection within these patients is required to highlight the eventual differential relation between the underlying neurobiological pathology, neuronal loss, and the effect of educational attainment or other more comprehensive CR indexes.

Methodological considerations

This retrospective and exploratory study utilized clinical and rsEEG datasets from the Consortium's archive (www.pdwaves.eu). It is based on data from multiple clinical units that did not follow harmonized data collection procedures as would be done in a prospective clinical trial. Furthermore, the clinical units only belonged to the Western Eurasia area, which limits the generalizability of our results to the world population. Based on the limited composition of the available cohort, we could only perform a control analysis using a linguistic-cultural background factor with two levels, namely Europe and Turkey. Results showed no effect of the linguistic-cultural background factor in the present design. However, we know that the relationship between educational attainment and cognitive reserve may be moderated by socioeconomic factors, as well as lifelong cultural and occupational activities. All of these aspects may vary considerably across countries, and an extension of the sample, including participants from different socio-economic and linguistic-cultural backgrounds, is required for future cross-validation.

Furthermore, we had access to a relatively small number of PDD and DLB datasets. Given the exploratory nature of this study, we employed a liberal statistical threshold of $p < 0.05$ in some analyses. The relatively small sample size did not allow us to directly compare the PDD and DLB groups due to their well-known different demographic features (e.g., age and sex). Furthermore, the limited number of Healthy, DLB, and PDD participants did not allow

us to use the same thresholds of low and high educational attainment in the Healthy, DLB, and PDD groups of the main statistical analysis. This problem was partially mitigated by the fact that those thresholds were very similar in the DLB and PDD groups. Indeed, both pathological groups showed mean low and high educational attainment levels of about 5 and 10 years, respectively. The mean of 5 years corresponds to the first cycle of school in most European countries, while the mean of 10 years includes subsequent cycles. However, we performed a control analysis that matched the educational attainment levels of the Edu- and Edu+ subgroups across the Healthy, DLB, and PDD participants. Results confirmed those obtained on the whole cohort.

In this study, educational attainment was used as a proxy for CR due to its simplicity, availability, and consistency in neurodegenerative disease research [15, 16]. Future studies should consider a broader range of CR indices, including those based on lifetime occupation and leisure activities, as well as residual cognitive performance after accounting for neuropathological and neurodegenerative factors [55].

In the present PDD group, residual cholinergic activity may contribute to the compensatory mechanisms maintaining cognitive status in patients with higher education attainment against more deranged rsEEG alpha rhythms when compared to patients with lower education attainment. Unfortunately, we could not test this possible explanation with molecular, structural, or functional neuroimaging evidence, making speculative the interpretation of the results.

The rsEEG recordings in this study were obtained using a 10–10 electrode montage system with 30 scalp electrodes. This may be sufficient for exploratory studies using source estimation techniques at low spatial resolution [39]. However, this approach limits the precision of cortical source localization, which was performed across large cortical regions of interest (e.g., cortical lobes) using eLORETA. While this method is suitable for modeling spatially widespread cortical source activations, future studies should employ high-resolution EEG techniques with 64–256 scalp electrodes to achieve higher spatial resolution in rsEEG source estimation [117, 118].

Finally, the rsEEG recordings were conducted in a single session, precluding longitudinal evaluation of CR effects on rsEEG rhythms in PDD and DLB patients. Future studies should adopt longitudinal,

multicentric, and prospective designs, incorporating large cohorts of PDD and DLB patients and more conservative statistical thresholds to reduce the risk of false-positive findings. Additionally, multimodal approaches combining rsEEG, MRI, and FDG-PET with harmonized longitudinal data collection procedures and biomarkers will likely offer a more comprehensive understanding of CR effects over the disease course.

Conclusions

This study investigated whether educational attainment, a typical CR proxy, influences rsEEG rhythms reflecting neurophysiological mechanisms underlying cortical arousal and vigilance regulation in PDD and DLB patients. For this purpose, cognitively unimpaired older adults served as a control group. Participants in each group were divided into low (Edu-) and high (Edu+) educational attainment subgroups.

In the Healthy group, participants with higher educational attainment (Edu+) exhibited significantly greater rsEEG alpha rhythms compared to those with lower educational attainment (Edu), potentially indicating neuroprotective neurophysiological mechanisms. In contrast, within the PDD group, widespread rsEEG alpha rhythms were lower in Edu+ patients compared to Edu- patients. This reduction in the rsEEG alpha activity might reflect compensatory mechanisms that help maintain cognitive-motor status in Edu+ patients despite the underlying disruption of such a rsEEG activity. Meanwhile, in the DLB group, no significant differences in rsEEG rhythms were observed between Edu+ and Edu- patients.

Our results suggest that in PDD patients, but not in DLB patients, higher educational attainment may compensate for abnormalities in the brain's neurophysiological oscillatory mechanisms that underlie rsEEG alpha rhythms and the regulation of vigilance. These findings underscore the profound significance of early-life education as a crucial component in strategies to fortify brain reserve against neurodegenerative diseases. This compelling evidence highlights how investing in education from a young age plays a pivotal role in bolstering cognitive resilience and protecting against the onset of these debilitating neurodegenerative conditions. More specifically, early-life education may represent one of the best investments

of national governments, especially in lower-income countries, for the prevention of cognitive deficits in PDD patients along aging, mitigating the unbearable social and economic burden of that pathological condition.

Future studies that combine rsEEG with neuroimaging techniques should explore the metabolic, neuromodulatory (e.g., cholinergic), and functional connectivity correlates of these hypothesized compensatory (resilient) mechanisms in the PDD brain. Additionally, research should investigate whether the absence of these compensatory effects in DLB patients is due to more severe dysfunctions in the associated neural correlates.

Author contribution Susanna Lopez: Conceptualization, formal analysis, methodology, validation, writing—original draft. Claudio Del Percio: Data curation, formal analysis, methodology validation. Roberta Lizio: Formal analysis. Giuseppe Noce: Formal analysis. Dharmendra Jakhar: Formal analysis. Andrea Soricelli: Resources, writing—review and editing. Marco Salvatore: Resources, writing—review and editing. Bahar Güntekin: Data curation, validation, writing—review and editing. Görsev Yener: Data curation, validation, writing—review and editing. Federico Massa: Data curation. Dario Arnaldi: Data curation, validation, writing—review and editing. Francesco Famà: Data curation. Matteo Pardini: Resources, writing—review and editing. Raffaele Ferri: Resources, supervision. Filippo Carducci: Formal analysis, writing—review and editing. Bartolo Lanuzza: Data curation. Fabrizio Stocchi: Resources. Laura Vacca: Resources. Chiara Coletti: Data curation. Moira Marizzoni: Data curation. John Paul Taylor: Data curation. Lutfu Hanoğlu: Data curation. Nesrin Helvacı Yılmaz: Data curation. İlayda Kıyı: Data curation. Yağmur Özbek-İşbitiren: Data curation. Anita D'Anselmo: Data curation. Laura Bonanni: Resources, writing—review and editing. Roberta Biundo: Data curation. Fabrizia D'Antonio: Data curation. Giuseppe Bruno: Resources. Angelo Antonini: Resources, writing—review and editing. Franco Giubilei: Resources. Sofia Cuoco: Data curation. Paolo Barone: Resources. Giovanni B. Frisoni: Resources. Rossella Rotondo: Data curation. Francesca De Pandis: Resources, supervision. Claudio Babiloni: Conceptualization, investigation, project administration, supervision, writing—review and editing.

Funding Open access funding provided by Università degli Studi di Roma La Sapienza within the CRUI-CARE Agreement. This study used data from the PDWAVES Consortium (www.pdwaves.eu). The partners and their respective institutional affiliations are listed on the cover page of this manuscript.

The clinical, neuropsychological, and magnetic resonance imaging data analyses were partially supported by funds of “Ricerca Corrente” attributed by the Italian Ministry of Health to the IRCCS Synlab SDN of Naples (Italy), Oasi Research Institute–IRCCS, Troina (Italy), IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli (Italy), IRCCS Ospedale

Policlinico San Martino, Genova (Italy), and IRCCS San Raffaele of Rome (Italy).

Susanna Lopez was supported by the grant “BE FOR ERC 2023” from the Sapienza University of Rome.

Claudio Del Percio was partially supported by the funds of the project eBRAIN-Health – Actionable Multilevel Health Data, Call and Sponsor: HORIZON 2021, HORIZON-INFRA-2021-TECH-01 (HORIZON-INFRA-2021-TECH-01–01—Interdisciplinary digital twins for modeling and simulating complex phenomena at the service of research infrastructure communities), Grant Agreement: GAP-101058516.

Roberta Lizio was supported by the funds of the project titled “Fast screening of cognitive and motor functions in elderly patients with cognitive-motor deficits using digital indices: a green telemedicine service to reduce the environmental impact of mobility related to the periodic assessment of cognitive functions in healthcare facilities” from the Call PON “Green-digital” resources for technological innovation and environmental sustainability (DM 1062/2021) Program of the Italian Ministry of University and Research.

Matteo Pardini was supported by the grant with the following reference: PE00000006 “PNRR MUR—M4 C2—MNESYS – A multiscale integrated approach to the study of the nervous system in health and disease (MNESYS)—EXTENDED PARTNERSHIP #12, SPOKE 6, CASCADE CALL from PNRR, Mission 4, Component 2 (CUP: D33C22001340002).

Fabrizio Stocchi was partially supported by the funds of the project titled “TELEmonitoraggio e neuromodulazione del ciclo sonno-veglia e della fluttuazione delle funzioni cognitive in pazienti con Malattie neurodegenerative: validazione di un tool di Intelligenza Artificiale (TELEMAIA)” from the Call “REGIONE LAZIO FOR COMPETITIVE REPURPOSING FOR RESEARCH-DEVELOPMENT-INNOVATION 2023.”

John-Paul Taylor was supported by the Newcastle NIHR Biomedical Research Centre.

Laura Bonanni was partially supported by the funds of the project “Assessment of brain functions in Lewy Body disease patients using telemonitoring DIGITAL markers as inputs to artificial intelligence (LBDigital),” Call and Sponsor: ANNUAL STRATEGIC PROGRAM OF ITALIAN MINISTRY OF UNIVERSITY AND SCIENTIFIC AND TECHNOLOGICAL RESEARCH, Grant Agreement: 2010SH7H3 F, PNRR Mission 4 Component 1 granted by European Union–NextGenerationEU, CUP: B53D23019150006.

Paolo Barone and Angelo Antonini were partially supported by the funds of the project “Effects of endogenous and exogenous risk factors in patients with Alzheimer’s and Parkinson’s diseases using clinical indexes and endophenotypes (biomarkers) as inputs to artificial intelligence” (PREDICT-NEURODEGEN), Call and Sponsor: ANNUAL STRATEGIC PROGRAM OF ITALIAN MINISTRY OF HEALTH, Grant Agreement: PNRR-MAD-2022–12376415.

Claudio Babiloni was partly supported by the grant Progetto ECS 0000024 Rome Technopole, CUP B83 C22002820006, PNRR Mission 4 Component 2 Investment 1.5, which was granted by the European Union–NextGenerationEU.

Data availability The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

Declarations

Ethics approval and consent to participate The local institutional ethical committees approved the study with the following references for each clinical unit:

Sapienza University of Rome (Italy): S. Andrea Hospital University Ethical Committee (Rome, Italy), Ref. 73/2012 of May 25, 2017

IRCCS “Fatebenefratelli” Brescia: IRCCS “Fatebenefratelli” Ethical Committee (Brescia, Italy), Prot. n 1024/2011/P of October 10, 2011

IRCCS Synlab SDN: IRCCS Synlab SDN Ethical Committee (Naples, Italy), Prot. 4–12 of September 21, 2012

Oasi Research Institute–IRCCS of Troina (Italy): IRCCS Sicilia–Oasi Maria SS Ethical Committee (Troina, Italy), Ref. 2022/04/05/CE–IRCCS–OASI/52 of April 5, 2022

University of Genova: Liguria Regional Ethics Committee (Genoa, Italy), Ref. 703 of May 31, 2013

Hospital San Raffaele of Cassino (Italy): Hospital San Raffaele of Cassino Ethical Committee (CE Lazio 2, Italy), Ref. 160–15 of 23 Nov 2016, n.0148158/2016

IRCCS San Raffaele Pisana of Rome (Italy): IRCCS San Raffaele Pisana Ethical Committee (Rome, Italy), Ref. 7/2014 of July 29, 2014

University “G. d’Annunzio” of Chieti-Pescara (Italy): Ethics Committee of the University “G. d’Annunzio” Chieti-Pescara, Ref. ID#157801

Translational and Clinical Research Institute of Newcastle University (UK): Newcastle and North Tyneside 1 Research Ethics Committee, Ref: 10/H0906/19 of May 13, 2010

Izmir University of Economics, Faculty of Medicine (Turkey): Dokuz Eylül University Ethical Committee (Izmir, Turkey), Prot no: 3815-GOA, Ref. No. 2018/05–09, of February 15, 2018

Medipol University of Istanbul (Turkey): Istanbul Medipol University Ethical Committee (Istanbul, Turkey), Ref. 10840098–604.01.01. of May 30, 2018

All experiments were conducted in accordance with the Code of Ethics of the World Medical Association (Declaration of Helsinki) and the standards established by the local institutional review boards. Informed and overt consent was obtained from each participant or caregiver prior to their participation.

Consent for publication Not applicable.

Competing interests The authors declare no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds

the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

1. Aarsland D, Litvan I, Salmon D, Galasko D, Wentzel-Larsen T, Larsen JP. Performance on the dementia rating scale in Parkinson’s disease with dementia and dementia with Lewy bodies: comparison with progressive supranuclear palsy and Alzheimer’s disease. *J Neurol Neurosurg Psychiatry*. 2003;74(9):1215–20. <https://doi.org/10.1136/jnnp.74.9.1215>.
2. Weisman D, McKeith I. Dementia with Lewy bodies. *Semin Neurol*. 2007;27(1):42–7. <https://doi.org/10.1055/s-2006-956754>.
3. Barker RA, Williams-Gray CH. The spectrum of clinical features seen with alpha-synuclein pathology. *Neuropathol Appl Neurobiol*. 2016;42(1):6–19. <https://doi.org/10.1111/nan.12303>.
4. Hall H, Reyes S, Landeck N, Bye C, Leanza G, Double K, et al. Hippocampal Lewy pathology and cholinergic dysfunction are associated with dementia in Parkinson’s disease. *Brain*. 2014;137(Pt 9):2493–508. <https://doi.org/10.1093/brain/awu193>.
5. Hepp DH, Vergoossen DL, Huisman E, Lemstra AW, Netherlands Brain Bank, Berendse HW, et al. Distribution and load of amyloid- β pathology in Parkinson disease and dementia with Lewy bodies. *J Neuropathol Exp Neurol*. 2016;75(10):936–45. <https://doi.org/10.1093/jnen/nlw070>.
6. McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. *Neurology*. 2017;89(1):88–100. <https://doi.org/10.1212/WNL.0000000000004058>.
7. Levy G, Tang MX, Cote LJ, Louis ED, Alfaró B, Mejia H, et al. Motor impairment in PD: relationship to incident dementia and age. *Neurology*. 2000;55(4):539–44. <https://doi.org/10.1212/wnl.55.4.539>.
8. Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, et al. Clinical diagnostic criteria for dementia associated with Parkinson’s disease. *Mov Disord*. 2007;22(12):1689–837. <https://doi.org/10.1002/mds.21507>.
9. Buter TC, van den Hout A, Matthews FE, Larsen JP, Brayne C, Aarsland D. Dementia and survival in Parkinson disease: a 12-year population study. *Neurology*. 2008;70(13):1017–22. <https://doi.org/10.1212/01.wnl.0000306632.43729.24>.
10. Walker Z, Possin KL, Boeve BF, Aarsland D. Lewy body dementias. *Lancet*. 2015;386(10004):1683–97. [https://doi.org/10.1016/S0140-6736\(15\)00462-6](https://doi.org/10.1016/S0140-6736(15)00462-6).
11. Stern Y. Cognitive reserve in ageing and Alzheimer’s disease. *Lancet Neurol*. 2012;11(11):1006–12. [https://doi.org/10.1016/S1474-4422\(12\)70191-6](https://doi.org/10.1016/S1474-4422(12)70191-6).
12. Nithianantharajah J, Hannan AJ. Enriched environments, experience-dependent plasticity, and

- disorders of the nervous system. *Nat Rev Neurosci*. 2006;7(9):697–709. <https://doi.org/10.1038/nrn1970>.
13. Valenzuela MJ, Breakspear M, Sachdev P. Complex mental activity and the aging brain: molecular, cellular and cortical network mechanisms. *Brain Res Rev*. 2007;56(1):198–213. <https://doi.org/10.1016/j.brainresrev.2007.07.007>.
 14. Teipel S, Grothe MJ, Zhou J, Sepulcre J, Dyrba M, Sorg C, et al. Measuring cortical connectivity in Alzheimer's disease as a brain neural network pathology: toward clinical applications. *J Int Neuropsychol Soc*. 2016;22(2):138–63. <https://doi.org/10.1017/S1355617715000995>.
 15. Stern Y, Arenaza-Urquijo EM, Bartrés-Faz D, et al. Whitepaper: Defining and investigating cognitive reserve, brain reserve, and brain maintenance. *Alzheimers Dement*. 2020;16(9):1305–11. <https://doi.org/10.1016/j.jalz.2018.07.219>.
 16. Stern Y, Albert M, Barnes CA, Cabeza R, Pascual-Leone A, Rapp PR. A framework for concepts of reserve and resilience in aging. *Neurobiol Aging*. 2023;124:100–3. <https://doi.org/10.1016/j.neurobiolaging.2022.10.015>.
 17. Gonzalez-Gomez R, Legaz A, Moguilner S, et al. Educational disparities in brain health and dementia across Latin America and the United States. *Alzheimers Dement*. Published online August 13, 2024. <https://doi.org/10.1002/alz.14085>.
 18. Farah MJ. The neuroscience of socioeconomic status: correlates, causes, and consequences. *Neuron*. 2017;96:56–71. <https://doi.org/10.1016/j.neuron.2017.08.034>.
 19. Ibáñez A, Legaz A, Ruiz-Adame M. Addressing the gaps between socioeconomic disparities and biological models of dementia. *Brain*. 2023;146(9):3561–4. <https://doi.org/10.1093/brain/awad236>.
 20. Hatzenbuehler ML, McLaughlin KA, Weissman DG, Cikara M. A research agenda for understanding how social inequality is linked to brain structure and function. *Nat Hum Behav*. 2024;8(1):20–31. <https://doi.org/10.1038/s41562-023-01774-8>.
 21. Hilal S, Brayne C. Epidemiologic trends, social determinants, and brain health: the role of life course inequalities. *Stroke*. 2022;53(2):437–43. <https://doi.org/10.1161/STROKEAHA.121.032609>.
 22. Wallhovd KB, Fjell AM, Wang Y, et al. Education and income show heterogeneous relationships to lifespan brain and cognitive differences across European and US cohorts. *Cereb Cortex*. 2022;32(4):839–54. <https://doi.org/10.1093/cercor/bhab248>.
 23. Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. *Lancet North Am Ed*. 2020;396(10248):413–46. [https://doi.org/10.1016/S0140-6736\(20\)30367-6](https://doi.org/10.1016/S0140-6736(20)30367-6).
 24. Katzman R, Terry R, DeTeresa R, Brown T, Davies P, Fuld P, et al. Clinical, pathological, and neurochemical changes in dementia: a subgroup with preserved mental status and numerous neocortical plaques. *Ann Neurol*. 1988;23(2):138–44. <https://doi.org/10.1002/ana.410230206>.
 25. Arenaza-Urquijo EM, Molinuevo JL, Sala-Llonch R, Solé-Padullés C, Balasa M, Bosch B, et al. Cognitive reserve proxies relate to gray matter loss in cognitively healthy elderly with abnormal cerebrospinal fluid amyloid- β levels. *J Alzheimers Dis*. 2013;35(4):715–26. <https://doi.org/10.3233/JAD-121906>.
 26. Bennett DA, Wilson RS, Schneider JA, Evans DA, Mendes de Leon CF, Arnold SE, et al. Education modifies the relation of AD pathology to level of cognitive function in older persons. *Neurology*. 2003;60(12):1909–15. <https://doi.org/10.1212/01.wnl.0000069923.64550.9f>.
 27. Valenzuela MJ, Sachdev P. Brain reserve and cognitive decline: a non-parametric systematic review. *Psychol Med*. 2006;36(8):1065–73. <https://doi.org/10.1017/S0033291706007744>.
 28. Sachdev PS, Valenzuela M. Brain and cognitive reserve. *Am J Geriatr Psychiatry*. 2009;17(3):175–8. <https://doi.org/10.1097/JGP.0b013e318196a661>.
 29. Reed BR, Mungas D, Farias ST, Harvey D, Beckett L, Widaman K, et al. Measuring cognitive reserve based on the decomposition of episodic memory variance. *Brain*. 2010;133(8):2196–209. <https://doi.org/10.1093/brain/awq154>.
 30. Buchman AS, Bennett DA. High CRP with “normal” cognition: a resilient phenotype in old age. *Neurology*. 2012;79(11):1078–9. <https://doi.org/10.1212/WNL.0b013e3182698df4>.
 31. Zahodne LB, Manly JJ, Brickman AM, Siedlecki KL, Decarli C, Stern Y. Quantifying cognitive reserve in older adults by decomposing episodic memory variance: replication and extension. *J Int Neuropsychol Soc*. 2013;19(8):854–62. <https://doi.org/10.1017/S1355617713000738>.
 32. Zahodne LB, Manly JJ, Brickman AM, Narkhede A, Griffith EY, Guzman VA, et al. Is residual memory variance a valid method for quantifying cognitive reserve? A longitudinal application. *Neuropsychologia*. 2015;77:260–6. <https://doi.org/10.1016/j.neuropsychologia.2015.09.009>.
 33. Serra L, Musicco M, Cercignani M, Torso M, Spanò B, Mastropasqua C, et al. Cognitive reserve and the risk for Alzheimer's disease: a longitudinal study. *Neurobiol Aging*. 2015;36(2):592–600. <https://doi.org/10.1016/j.neurobiolaging.2014.10.010>.
 34. Arenaza-Urquijo EM, Vemuri P. Resistance vs resilience to Alzheimer disease: clarifying terminology for preclinical studies. *Neurology*. 2018;90(15):695–703. <https://doi.org/10.1212/WNL.0000000000005303>.
 35. Garibotto V, Borroni B, Kalbe E, Herholz K, Salmon E, Holtorf V, et al. Education and occupation as proxies for reserve in aMCI converters and AD: FDG-PET evidence. *Neurology*. 2008;71(17):1342–9. <https://doi.org/10.1212/01.wnl.0000327670.62378.c0>.
 36. Morbelli S, Nobili F. Cognitive reserve and clinical expression of Alzheimer's disease: evidence and implications for brain PET imaging. *Am J Nucl Med Mol Imaging*. 2014;4(3):239–47.
 37. Hampel H, Lista S, Neri C, Vergallo A. Time for the systems-level integration of aging: resilience enhancing

- strategies to prevent Alzheimer's disease. *Prog Neurobiol.* 2019;181:101662. <https://doi.org/10.1016/j.pneurobio.2019.101662>.
38. Brayne C, Ince PG, Keage HA, McKeith IG, Matthews FE. Education, the brain and dementia: neuroprotection or compensation? *Brain.* 2010;133(Pt 8):2210–6. <https://doi.org/10.1093/brain/awq185>.
 39. Babiloni C, Barry RJ, Başar E, Blinowska KJ, Cichocki A, Drinkenburg WHIM, et al. International Federation of Clinical Neurophysiology (IFCN) - EEG research workgroup: Recommendations on the frequency and topographic analysis of resting state EEG rhythms. Part 1: Applications in clinical research studies. *Clin Neurophysiol.* 2020;131(1):285–307. <https://doi.org/10.1016/j.clinph.2019.06.234>.
 40. Babiloni C, Lopez S, Del Percio C, Noce G, Pascarelli MT, Lizio R, et al. Resting-state posterior alpha rhythms are abnormal in subjective memory complaint seniors with preclinical Alzheimer's neuropathology and high education level: the INSIGHT-preAD study. *Neurobiol Aging.* 2020;90:43–59. <https://doi.org/10.1016/j.neurobiolaging.2020.01.012>.
 41. Lopez S, Hampel H, Chiesa PA, Del Percio C, Noce G, Lizio R, et al. The association between posterior resting-state EEG alpha rhythms and functional MRI connectivity in older adults with subjective memory complaint. *Neurobiol Aging.* 2024;137:62–77. <https://doi.org/10.1016/j.neurobiolaging.2024.02.008>.
 42. Del Ser T, Hachinski V, Merskey H, Munoz DG. An autopsy-verified study of the effect of education on degenerative dementia. *Brain.* 1999;122(Pt 12):2309–19. <https://doi.org/10.1093/brain/122.12.2309>.
 43. Hindle JV, Martyr A, Clare L. Cognitive reserve in Parkinson's disease: a systematic review and meta-analysis. *Parkinsonism Relat Disord.* 2014;20(1):1–7. <https://doi.org/10.1016/j.parkreldis.2013.08.010>.
 44. Poletti M, Emre M, Bonuccelli U. Mild cognitive impairment and cognitive reserve in Parkinson's disease. *Parkinsonism Relat Disord.* 2011;17(8):579–86. <https://doi.org/10.1016/j.parkreldis.2011.03.013>.
 45. Glatt SL, Hubble JP, Lyons K, Paolo A, Troster AI, Hassanein RE. Risk factors for dementia in Parkinson's disease: effect of education. *Neuroepidemiology.* 1996;15(1):20–5. <https://doi.org/10.1159/000109885>.
 46. Pernecky R, Häussermann P, Drzezga A, Boecker H, Granert O, Feurer R, et al. Fluoro-deoxy-glucose positron emission tomography correlates of impaired activities of daily living in dementia with Lewy bodies: implications for cognitive reserve. *Am J Geriatr Psychiatry.* 2009;17(3):188–95. <https://doi.org/10.1097/JGP.0b013e3181961a6f>.
 47. Barulli D, Stern Y. Efficiency, capacity, compensation, maintenance, plasticity: emerging concepts in cognitive reserve. *Trends Cogn Sci.* 2013;17(10):502–9. <https://doi.org/10.1016/j.tics.2013.08.012>.
 48. Blume J, Rothenfusser E, Schlaier J, Bogdahn U, Lange M. Educational attainment and motor burden in advanced Parkinson's disease - The emerging role of education in motor reserve. *J Neurol Sci.* 2017;381:141–3. <https://doi.org/10.1016/j.jns.2017.08.3241>.
 49. Ciccarelli N, Monaco MRL, Fusco D, Vetrano DL, Zucalà G, Bernabei R, et al. The role of cognitive reserve in cognitive aging: what we can learn from Parkinson's disease. *Aging Clin Exp Res.* 2018;30(7):877–80. <https://doi.org/10.1007/s40520-017-0838-0>.
 50. Ciccarelli N, Colombo B, Pepe F, Magni E, Antonietti A, Silveri MC. Cognitive reserve: a multidimensional protective factor in Parkinson's disease related cognitive impairment. *Aging Neuropsychol Cogn.* 2022;29(4):687–702. <https://doi.org/10.1007/s40520-017-0838-0>.
 51. Guzzetti S, Mancini F, Caporali A, Manfredi L, Daini R. The association of cognitive reserve with motor and cognitive functions for different stages of Parkinson's disease. *Exp Gerontol.* 2019;115:79–87. <https://doi.org/10.1016/j.exger.2018.11.020>.
 52. Carli G, Boccalini C, Vanoli G, Filippi M, Iannaccone S, Magnani G, Perani D. Specific occupational profiles as proxies of cognitive reserve induce neuroprotection in dementia with Lewy bodies. *Brain Imaging Behav.* 2021;15(3):1427–37. <https://doi.org/10.1007/s11682-020-00342-2>.
 53. Loftus AM, Gasson N, Lopez N, Sellner M, Reid C, Cocks N, et al. Cognitive reserve, executive function, and memory in Parkinson's disease. *Brain Sci.* 2021;11(8):992. <https://doi.org/10.3390/brainsci11080992>.
 54. Gu L, Xu H. Effect of cognitive reserve on cognitive function in Parkinson's disease. *Neurol Sci.* 2022;43(7):4185–92. <https://doi.org/10.1007/s10072-022-05985-1>.
 55. Saywell I, Foreman L, Child B, Phillips-Hughes AL, Collins-Praino L, Baetu I. Influence of cognitive reserve on cognitive and motor function in alpha-synucleinopathies: a systematic review and multilevel meta-analysis. *Neurosci Biobehav Rev.* 2024;161:105672. <https://doi.org/10.1016/j.neubiorev.2024.105672>.
 56. Lucero C, Campbell MC, Flores H, Maiti B, Perlmutter JS, Foster ER. Cognitive reserve and beta-amyloid pathology in Parkinson disease. *Parkinsonism Relat Disord.* 2015;21(8):899–904. <https://doi.org/10.1016/j.parkreldis.2015.05.020>.
 57. Fernández-Rodríguez B, Rodríguez-Rojas R, Guida P, Angulo-Díaz-Parreño S, Trompeta C, Mata-Marín D, et al. Cognitive reserve in Parkinson's disease without dementia: β -amyloid and metabolic assessment. *Mov Disord Clin Pract.* 2024;11(3):282–8. <https://doi.org/10.1002/mdc3.13967>.
 58. Pernecky R, Häussermann P, Diehl-Schmid J, Boecker H, Förstl H, Drzezga A, Kurz A. Metabolic correlates of brain reserve in dementia with Lewy bodies: An FDG PET study. *Dement Geriatr Cogn Disord.* 2007;23(6):416–22. <https://doi.org/10.1159/000101956>.
 59. Pernecky R, Drzezga A, Diehl-Schmid J, et al. Schooling mediates brain reserve in Alzheimer's disease: findings of fluoro-deoxy-glucose-positron emission tomography. *J Neurol Neurosurg Psychiatry.* 2006;77(9):1060–3. <https://doi.org/10.1136/jnnp.2006.094714>.
 60. Bauckneht M, Chincarini A, Piva R, Arnaldi D, Girtler N, Massa F, et al. Metabolic correlates of reserve and resilience in MCI due to Alzheimer's disease (AD).

- Alzheimers Res Ther. 2018;10(1):35. <https://doi.org/10.1186/s13195-018-0366-y>.
61. Morbelli S, Chincarini A, Brendel M, Rominger A, et al. Metabolic patterns across core features in dementia with Lewy bodies. *Ann Neurol*. 2019;85:715–25. <https://doi.org/10.1002/ana.25453>.
 62. Di Tella S, Isernia S, Cabinio M, Rossetto F, Borgnis F, Pagliari C, et al. Cognitive reserve proxies can modulate motor and non-motor basal ganglia circuits in early Parkinson's disease. *Brain Imaging Behav*. 2024;18(1):220–30. <https://doi.org/10.1007/s11682-023-00829-8>.
 63. Lamotte G, Morello R, Lebasnier A, Agostini D, Bouvard G, De La Sayette V, Defer GL. Influence of education on cognitive performance and dopamine transporter binding in dementia with Lewy bodies. *Clin Neurol Neurosurg*. 2016;146:138–43. <https://doi.org/10.1016/j.clineuro.2016.05.009>.
 64. Di Tella S, De Marco M, Baglio F, Silveri MC, Venneri A. Resting-state functional connectivity is modulated by cognitive reserve in early Parkinson's disease. *Front Psychol*. 2023;14:1207988. <https://doi.org/10.3389/fpsyg.2023.1207988>.
 65. Babiloni C. The dark side of Alzheimer's disease: neglected physiological biomarkers of brain hyperexcitability and abnormal consciousness level. *J Alzheimers Dis*. 2022;88(3):801–7. <https://doi.org/10.3233/JAD-220582>.
 66. Walker MP, Ayre GA, Perry EK, Wesnes K, McKeith IG, Tovee M, et al. Quantification and characterization of fluctuating cognition in dementia with Lewy bodies and Alzheimer's disease. *Dement Geriatr Cogn Disord*. 2000;11(6):327–35. <https://doi.org/10.1159/000017262>.
 67. Walker MP, Ayre GA, Cummings JL, Wesnes K, McKeith IG, O'Brien JT, Ballard CG. The clinician assessment of fluctuation and the one day fluctuation assessment scale. Two methods to assess fluctuating confusion in dementia. *Br J Psychiatry*. 2000;177:252–6. <https://doi.org/10.1192/bjp.177.3.252>.
 68. Kai T, Asai Y, Sakuma K, Koeda T, Nakashima K. Quantitative electroencephalogram analysis in dementia with Lewy bodies and Alzheimer's disease. *J Neurol Sci*. 2005;237(1–2):89–95. <https://doi.org/10.1016/j.jns.2005.05.017>.
 69. Serizawa K, Kamei S, Morita A, Hara M, Mizutani T, Yoshihashi H, et al. Comparison of quantitative EEGs between Parkinson disease and age-adjusted normal controls. *J Clin Neurophysiol*. 2008;25(6):361–6. <https://doi.org/10.1097/WNP.0b013e31818f50de>.
 70. Bonanni L, Thomas A, Tiraboschi P, Perfetti B, Varanese S, Onofrj M. EEG comparisons in early Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease with dementia patients with a 2-year follow-up. *Brain*. 2008;131(Pt 3):690–705. <https://doi.org/10.1093/brain/awm322>.
 71. Jackson J, Young CK, Hu B, Bland BH. High-frequency stimulation of the posterior hypothalamic nucleus restores movement and reinstates hippocampal-striatal theta coherence following haloperidol-induced catalepsy. *Exp Neurol*. 2008;213(1):210–9. <https://doi.org/10.1016/j.expneurol.2008.06.007>.
 72. Kamei S, Morita A, Serizawa K, Mizutani T, Hiray-anagi K. Quantitative EEG analysis of executive dysfunction in Parkinson disease. *J Clin Neurophysiol*. 2010;27:193–7. <https://doi.org/10.1097/WNP.0b013e3181dd4fdb>.
 73. Pugnetti L, Baglio F, Farina E, Alberoni M, Calabrese E, Gambini A, et al. EEG evidence of posterior cortical disconnection in PD and related dementias. *Int J Neurosci*. 2010;120(2):88–98. <https://doi.org/10.3109/00207450903436346>.
 74. Babiloni C, Del Percio C, Lizio R, Noce G, Cordone S, Lopez S, et al. Abnormalities of cortical neural synchronization mechanisms in patients with dementia due to Alzheimer's and Lewy body diseases: an EEG study. *Neurobiol Aging*. 2017;55:143–58. <https://doi.org/10.1016/j.neurobiolaging.2017.03.030>.
 75. Pascarelli MT, Del Percio C, De Pandis MF, Ferri R, Lizio R, Noce G, et al. Abnormalities of resting-state EEG in patients with prodromal and overt dementia with Lewy bodies: relation to clinical symptoms. *Clin Neurophysiol*. 2020;131(11):2716–31. <https://doi.org/10.1016/j.clinph.2020.09.004>.
 76. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. *Arch Neurol*. 1999;56(1):33–9. <https://doi.org/10.1016/j.clinph.2020.09.004>.
 77. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. *Neurology*. 1967;17(5):427–42. <https://doi.org/10.1212/wnl.17.5.427>.
 78. Fahn S, Elton R, and Members of the UPDRS Development Committee. The unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M (eds). *Recent Developments in Parkinson's Disease*. Vol. 2. Florham Park: McMellam Health Care Information; 1987;153–63.
 79. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. *Neurology*. 1994;44(12):2308–14. <https://doi.org/10.1212/wnl.44.12.2308>.
 80. Dubois B, Slachevsky A, Litvan I, Pillon B. The FAB: a frontal assessment battery at bedside. *Neurology*. 2000;55(11):1621–6. <https://doi.org/10.1212/wnl.55.11.1621>.
 81. Novelli G, Papagno C, Capitani E, Laiacona M. Tre test clinici di ricerca e produzione lessicale. Taratura su soggetti normali. *Arch Psicol Neurol Psichiatr*. 1986;47(4):477–506.
 82. Benton AL, Varney NR, Hamsher KD. Visuospatial judgment. A clinical test. *Arch Neurol*. 1978;35(6):364–7. <https://doi.org/10.1001/archneur.1978.00500300038006>.
 83. Benton AL, Sivan AB, Hamsher KD, Varney NR, Spreen O. Facial recognition: Stimulus and multiple-choice pictures. In: Benton AL, Sivan AB, Hamsher KD, Varney NR, Spreen O, editors. *Contribution to neuropsychological assessment*. Oxford: Oxford University Press; 1983. p. 30–40.
 84. Reitan RM. Validity of the trail making test as an indicator of organic brain damage. *Percept Mot Skills*. 1958;8(3):271–6.

85. Stroop JR. Studies of interference in serial verbal reactions. *J Exp Psychol.* 1935;18(6):643–62.
86. Inouye SK, van Dyck CH, Alessi CA, Balkin S, Siegal AP, Horwitz RI. Clarifying confusion: the confusion assessment method. A new method for detection of delirium. *Ann Intern Med.* 1990;113(12):941–8. <https://doi.org/10.7326/0003-4819-113-12-941>.
87. Wechsler D. Wechsler Memory Scale—Third edition manual. San Antonio, TX: Psychological Corporation; 1997.
88. Öktem Ö. Sözel bellek süreçleri testi (bir ön çalışma). *Nöropsikiyatri Arşivi.* 1992;29:196–206.
89. Delorme A, Makeig S. EEGLAB: an open source toolbox for analysis of single-trial EEG dynamics including independent component analysis. *J Neurosci Methods.* 2004;134(1):9–21. <https://doi.org/10.1016/j.jneumeth.2003.10.009>.
90. Pascual-Marqui RD. Discrete, 3D distributed, linear imaging methods of electric neuronal activity. Part 1: exact, zero error localization. [arXiv:0710.3341 \[math-ph\]](https://arxiv.org/pdf/0710.3341) Available at <http://arxiv.org/pdf/0710.3341>.
91. Karimi F, Niu J, Gouweleeuw K, Almeida Q, Jiang N. Movement-related EEG signatures associated with freezing of gait in Parkinson's disease: an integrative analysis. *Brain Commun.* 2021;3(4):fcab277. <https://doi.org/10.1093/braincomms/fcab277>.
92. Berger H. Über das Elektrenkephalogramm des Menschen. *Archiv f Psychiatrie.* 1929;87:527–70. <https://doi.org/10.1007/BF01797193>.
93. Pfurtscheller G, Lopes da Silva FH. Event-related EEG/MEG synchronization and desynchronization: basic principles. *Clin Neurophysiol.* 1999;110(11):1842–57. [https://doi.org/10.1016/s1388-2457\(99\)00141-8](https://doi.org/10.1016/s1388-2457(99)00141-8).
94. de Munck JC, Gonçalves SI, Huijboom L, Kuijjer JP, Pouwels PJ, Heethaar RM, et al. The hemodynamic response of the alpha rhythm: an EEG/fMRI study. *Neuroimage.* 2007;35(3):1142–51. <https://doi.org/10.1016/j.neuroimage.2007.01.022>.
95. Olbrich S, Mulert C, Karch S, Trenner M, Leicht G, Pogarell O, et al. EEG-vigilance and BOLD effect during simultaneous EEG/fMRI measurement. *Neuroimage.* 2009;45(2):319–32. <https://doi.org/10.1016/j.neuroimage.2008.11.014>.
96. Knaut P, von Wegner F, Morzelewski A, Laufs H. EEG-correlated fMRI of human alpha (de-)synchronization. *Clin Neurophysiol.* 2019;130(8):1375–86. <https://doi.org/10.1016/j.clinph.2019.04.715>.
97. Laufs H, Holt JL, Elfont R, Krams M, Paul JS, Krakow K, et al. Where the BOLD signal goes when alpha EEG leaves. *Neuroimage.* 2006;31(4):1408–18. <https://doi.org/10.1016/j.neuroimage.2006.02.002>.
98. Fleck JI, Kuti J, Mercurio J, Mullen S, Austin K, Pereira O. The impact of age and cognitive reserve on resting-state brain connectivity. *Front Aging Neurosci.* 2017;9:392. <https://doi.org/10.3389/fnagi.2017.00392>.
99. Fleck JI, Arnold M, Dykstra B, Casario K, Douglas E, Morris O. Distinct functional connectivity patterns are associated with social and cognitive lifestyle factors: pathways to cognitive reserve. *Front Aging Neurosci.* 2019;11:310. <https://doi.org/10.3389/fnagi.2019.00310>.
100. Baakman AC, Gavan C, van Doeselaar L, de Kam M, Broekhuizen K, Bajenaru O, et al. Acute response to cholinergic challenge predicts long-term response to galantamine treatment in patients with Alzheimer's disease. *Br J Clin Pharmacol.* 2022;88(6):2814–29. <https://doi.org/10.1111/bcp.15206>.
101. Babiloni C, Cassetta E, Dal Forno G, Del Percio C, Ferreri F, Ferri R, et al. Donepezil effects on sources of cortical rhythms in mild Alzheimer's disease: responders vs. non-responders. *Neuroimage.* 2006;31(4):1650–65. <https://doi.org/10.1016/j.neuroimage.2006.02.015>.
102. Soininen H, Reinikainen K, Partanen J, Mervaala E, Paljärvi L, Helkala EL, Riekkinen P Sr. Slowing of the dominant occipital rhythm in electroencephalogram is associated with low concentration of noradrenaline in the thalamus in patients with Alzheimer's disease. *Neurosci Lett.* 1992;137(1):5–8. [https://doi.org/10.1016/0304-3940\(92\)90285-f](https://doi.org/10.1016/0304-3940(92)90285-f).
103. Araújo-Silva F, Santinelli FB, Imaizumi LFI, Silveira APB, Vieira LHP, Alcock L, et al. Temporal dynamics of cortical activity and postural control in response to the first levodopa dose of the day in people with Parkinson's disease. *Brain Res.* 2022;1775:147727. <https://doi.org/10.1016/j.brainres.2021.147727>.
104. Koren O, Bartsch RP, Katzir Z, Rosenblum U, Hassin-Baer S, Inzelberg R, et al. Dopaminergic medication reduces interhemispheric hyper-synchronization in Parkinson's disease. *Parkinsonism Relat Disord.* 2022;97:39–46. <https://doi.org/10.1016/j.parkreldis.2022.02.009>.
105. Kemp AF, Kinnerup M, Johnsen B, Jakobsen S, Nahimi A, Gjedde A. EEG frequency correlates with $\alpha 2$ -receptor density in Parkinson's disease. *Biomolecules.* 2024;14(2):209. <https://doi.org/10.3390/biom14020209>.
106. Lorek K, Mączewska J, Królicki L, Siemiatycka M, Chalimoniuk M, Kisiel-Sajewicz K, et al. Slowing of EEG waves correlates with striatal [18 F]fluorodopa PET/CT uptake and executive dysfunction in Parkinson's disease. *Eur J Neurosci.* 2023;58(9):4070–83. <https://doi.org/10.1111/ejn.16156>.
107. Rea RC, Berlot R, Martin SL, Craig CE, Holmes PS, Wright DJ, et al. Quantitative EEG and cholinergic basal forebrain atrophy in Parkinson's disease and mild cognitive impairment. *Neurobiol Aging.* 2021;106:37–44. <https://doi.org/10.1016/j.neurobiolaging.2021.05.023>.
108. Marmor A, Vakil E, Kahana Merhavi S, Meiner Z. The complex interplay between cognitive reserve, age of diagnosis and cognitive decline in Alzheimer's disease: a retrospective study. *J Clin Exp Neuropsychol.* 2024;46:683–92. <https://doi.org/10.1080/13803395.2024.2400109>.
109. Biundo R, Weis L, Fiorenzato E, et al. The contribution of beta-amyloid to dementia in Lewy body diseases: a 1-year follow-up study. *Brain Commun.* 2021;3(3):fcab180. <https://doi.org/10.1093/braincomms/fcab180>.
110. Kantarci K, Lowe VJ, Chen Q, Przybelski SA, Lesnick TG, Schwarz CG, et al. β -Amyloid PET and neuropathology in dementia with Lewy bodies. *Neurology.*

- 2020;94(3):e282–91. <https://doi.org/10.1212/WNL.0000000000008818>.
111. Baik K, Kim HR, Park M, Lee Y, Na HK, Sohn YH, et al. Effect of amyloid on cognitive performance in Parkinson's disease and dementia with Lewy bodies. *Mov Disord*. 2023;38(2):278–85. <https://doi.org/10.1002/mds.29295>.
 112. Jellinger KA. Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies. *J Neural Transm (Vienna)*. 2018;125(4):615–50. <https://doi.org/10.1007/s00702-017-1821-9>.
 113. McAleese KE, Walker L, Erskine D, Thomas AJ, McKeith IG, Attems J. TDP-43 pathology in Alzheimer's disease, dementia with Lewy bodies and ageing. *Brain Pathol*. 2017;27(4):472–9. <https://doi.org/10.1111/bpa.12424>.
 114. Walker Z, Costa DC, Walker RW, Lee L, Livingston G, Jaros E, et al. Striatal dopamine transporter in dementia with Lewy bodies and Parkinson disease: a comparison. *Neurology*. 2004;62(9):1568–72. <https://doi.org/10.1212/01.wnl.0000123248.39847.1d>.
 115. Rolinski M, Fox C, Maidment I, McShane R. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease. *Cochrane Database Syst Rev*. 2012;2012(3):CD006504. <https://doi.org/10.1002/14651858.CD006504.pub2>.
 116. Meng YH, Wang PP, Song YX, Wang JH. Cholinesterase inhibitors and memantine for Parkinson's disease dementia and Lewy body dementia: a meta-analysis. *Exp Ther Med*. 2019;17(3):1611–24. <https://doi.org/10.3892/etm.2018.7129>.
 117. Liu AK, Dale AM, Belliveau JW. Monte Carlo simulation studies of EEG and MEG localization accuracy. *Hum Brain Mapp*. 2002;16(1):47–62. <https://doi.org/10.1002/hbm.10024>.
 118. Marino M, Liu Q, Brem S, Wenderoth N, Mantini D. Automated detection and labeling of high-density EEG electrodes from structural MR images. *J Neural Eng*. 2016;13(5):056003. <https://doi.org/10.1088/1741-2560/13/5/056003>.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.